Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application
Lead Research Organisation:
University of Cambridge
Department Name: Public Health and Primary Care
Abstract
If medical studies can reliably demonstrate that a particular factor is relevant to heart disease, then this could have important implications for the prediction and prevention of disease, as, for example, is now the case with measurement and modification of blood LDL("bad")-cholesterol levels.
Unfortunately, attempts using conventional approaches to identify risk factors that have cause-and-effect relationships with heart disease have often yielded costly failures in drug trials of new medicines.
Similarly, only modest improvements have been achieved in the prediction of heart disease with incremental modifications to conventional approaches.
Our research plan offers a fundamentally new approach to address these problems by combining the precision of molecular measurements with the power of large-scale population health studies. The deep integration of cutting-edge technologies for genetic and biochemical measurement technologies with extremely large and mature biomedical surveys ("epidemiological studies") of heart disease will yield studies that combine unprecedented power and detail.
In particular, for 50,000 people with heart attacks and 50,000 controls, we have for each participant, already recorded extensive detail about:
-genetic make-up (eg, up to one million genetic variants or "letters")
-blood biochemistry (eg, up to a few hundred analytes)
-lifestyle and other habits (eg, diet, physical activity, tobacco and alcohol consumption).
In the most informative subsets of these participants, we will conduct state-of-the-art measurements to supplement this extensive existing information. A key advantage of blood measurement methods called "lipidomics" and "metabonomics" should be that, although they relate to biochemical processes likely to be relevant to the causation of heart attacks (ie, fat and sugar metabolism, respectively), they cast wide scientific nets. This should avoid premature assumptions about the identity of the precise factors that might emerge to be relevant to heart disease.
Furthermore, as funding has already been awarded for "lipidomics" and "metabonomics" assays in 15,000 "control" participants in one of our studies (which we share with a study of new-onset type 2 diabetes), we will achieve major scientific synergy and cost savings by conducting concurrently the same assays in patients with new onset heart disease.
To help harvest the complex and rich data that will emerge from our studies in a rigorous and principled manner, our team includes world leaders in biostatistics. We will build on innovative approaches that we have previously developed to help distinguish causal from non-causal factors in heart disease.
The objective will be to discover entirely new causes of heart disease as well as to evaluate a variety of factors already suspected in heart disease, such as blood fats, sugar metabolism, "inflammation" (which is the body's response to injury), and nutritional factors.
We will use the same databases (supplemented by additional sources of information) to develop and test a range of approaches that have potential to improve the prediction of first-onset heart disease, such as those that:
-maximise accuracy of the prediction of heart disease, such as detailed scores containing genetic and biochemical information, which may be especially relevant to young people contemplating a lifetime of preventive therapy or to people with a strong family history of heart disease
-promote efficiency for health services, eg, "sequential" screening, which initially involves comparatively simple tests for everyone, then focusing more costly and detailed measurements on individuals initially identified as being most likely to benefit from further assessment.
Unfortunately, attempts using conventional approaches to identify risk factors that have cause-and-effect relationships with heart disease have often yielded costly failures in drug trials of new medicines.
Similarly, only modest improvements have been achieved in the prediction of heart disease with incremental modifications to conventional approaches.
Our research plan offers a fundamentally new approach to address these problems by combining the precision of molecular measurements with the power of large-scale population health studies. The deep integration of cutting-edge technologies for genetic and biochemical measurement technologies with extremely large and mature biomedical surveys ("epidemiological studies") of heart disease will yield studies that combine unprecedented power and detail.
In particular, for 50,000 people with heart attacks and 50,000 controls, we have for each participant, already recorded extensive detail about:
-genetic make-up (eg, up to one million genetic variants or "letters")
-blood biochemistry (eg, up to a few hundred analytes)
-lifestyle and other habits (eg, diet, physical activity, tobacco and alcohol consumption).
In the most informative subsets of these participants, we will conduct state-of-the-art measurements to supplement this extensive existing information. A key advantage of blood measurement methods called "lipidomics" and "metabonomics" should be that, although they relate to biochemical processes likely to be relevant to the causation of heart attacks (ie, fat and sugar metabolism, respectively), they cast wide scientific nets. This should avoid premature assumptions about the identity of the precise factors that might emerge to be relevant to heart disease.
Furthermore, as funding has already been awarded for "lipidomics" and "metabonomics" assays in 15,000 "control" participants in one of our studies (which we share with a study of new-onset type 2 diabetes), we will achieve major scientific synergy and cost savings by conducting concurrently the same assays in patients with new onset heart disease.
To help harvest the complex and rich data that will emerge from our studies in a rigorous and principled manner, our team includes world leaders in biostatistics. We will build on innovative approaches that we have previously developed to help distinguish causal from non-causal factors in heart disease.
The objective will be to discover entirely new causes of heart disease as well as to evaluate a variety of factors already suspected in heart disease, such as blood fats, sugar metabolism, "inflammation" (which is the body's response to injury), and nutritional factors.
We will use the same databases (supplemented by additional sources of information) to develop and test a range of approaches that have potential to improve the prediction of first-onset heart disease, such as those that:
-maximise accuracy of the prediction of heart disease, such as detailed scores containing genetic and biochemical information, which may be especially relevant to young people contemplating a lifetime of preventive therapy or to people with a strong family history of heart disease
-promote efficiency for health services, eg, "sequential" screening, which initially involves comparatively simple tests for everyone, then focusing more costly and detailed measurements on individuals initially identified as being most likely to benefit from further assessment.
Technical Summary
With separate funding, we have established a consortium of 50,000 first-onset CHD cases and 50,000 controls, including ~25,000 incident CHD cases and ~25,000 controls from "nested" case-control or case-cohort subsets in population-based prospective studies. All are sharing extensive individual participant data.
For all 100,000 participants, we are assaying a novel gene array (Exome+), as well as CardioMetabochip and genomewide association arrays in ~60,000 participants. These arrays furnish complementary data, enabling: i) study of >310,000 coding variants ii) dense fine-mapping of 360 priority loci (eg, >100 loci nominated by pharma, reflecting industry's priorities) iii) deep replication of previously identified promising variants and iv) imputation of 15 million additional variants.
In large subsets, we are assaying ~200 soluble biomarkers of potential vascular relevance, eg: i) a panel of phospholipid fatty acids ii) pro-atherogenic and/or pro-inflammatory lipids iii) adipocytokines, endocrine factors iv) carotenoids and vitamins.
We now propose to conduct lipidomics, metabonomics, and detailed inflammation biomarker assays in key subsets of these participants, capitalising on recent strategic investment in MRC labs.
This combination of exceptional statistical power, access to individual-level data, extensive genotyping, and extensive phenotyping should provide great opportunities for: i) discovery ii) causal analysis (using Mendelian randomisation analysis) and iii) advancement of disease prediction strategies.
To meet the challenges of analysing such exceptionally large and detailed datasets, we have assembled a world-leading analytical team led by the current, and the recent former, Directors of the MRC Biostatistics Unit. To hasten translation of findings, we have made arrangements for a variety of follow-on studies.
To execute our plan, we seek support to maintain a core subset of our existing scientific team.
For all 100,000 participants, we are assaying a novel gene array (Exome+), as well as CardioMetabochip and genomewide association arrays in ~60,000 participants. These arrays furnish complementary data, enabling: i) study of >310,000 coding variants ii) dense fine-mapping of 360 priority loci (eg, >100 loci nominated by pharma, reflecting industry's priorities) iii) deep replication of previously identified promising variants and iv) imputation of 15 million additional variants.
In large subsets, we are assaying ~200 soluble biomarkers of potential vascular relevance, eg: i) a panel of phospholipid fatty acids ii) pro-atherogenic and/or pro-inflammatory lipids iii) adipocytokines, endocrine factors iv) carotenoids and vitamins.
We now propose to conduct lipidomics, metabonomics, and detailed inflammation biomarker assays in key subsets of these participants, capitalising on recent strategic investment in MRC labs.
This combination of exceptional statistical power, access to individual-level data, extensive genotyping, and extensive phenotyping should provide great opportunities for: i) discovery ii) causal analysis (using Mendelian randomisation analysis) and iii) advancement of disease prediction strategies.
To meet the challenges of analysing such exceptionally large and detailed datasets, we have assembled a world-leading analytical team led by the current, and the recent former, Directors of the MRC Biostatistics Unit. To hasten translation of findings, we have made arrangements for a variety of follow-on studies.
To execute our plan, we seek support to maintain a core subset of our existing scientific team.
Planned Impact
In addition to the academic benefits described above, this proposal has the potential to contribute to industry and public policy:
1) Industry
Our research will directly address three inter-related issues underlying the high rate of failure in medicines development: a) identification of new therapeutic targets b) validation of proposed therapeutic targets and c) stratified approaches to test new agents.
Our findings should feed swiftly into senior R&D decision-making, both at pharmaceutical companies and small and medium-sized enterprises in the biotechnology sector, because:
-industry partners (Merck, Novartis, Pfizer) have co-funded genetic assays for our 100,000-person consortium on a pre-competitive basis, and they will follow the results closely because we have regular meetings and other mechanisms in place (see Pathways to Impact)
-we will continue to work closely with industry to hasten medicines development, exemplified by establishment of the Pfizer-Cambridge Centre for CVD Genomics in our department in 2011 (which has attracted 2 MRC CASE industrial PhD awards and NIHR co-funding)
-we have regular opportunities to engage with senior industry decision-makers, eg: the CEU has strategic collaborations with several industry partners. As noted above, JD is on the international scientific advisory boards of pharmaceutical and biotechnology companies.
The enthusiasm of industry for our proposal is demonstrated by the attached letters of support from:
Merck: Dr M Mendelsohn, Global Franchise Head, Atherosclerosis and CVD, and Dr D Bloomfield, Global Head of CVD Discovery
Novartis: Dr L Letvak, Global Development Franchise Head, Critical Care, and Dr D Keefe, Global Program Head, Lipids
Pfizer: Dr T Rolph, Chief Scientific Officer, Global Cardiovascular Franchise, and Dr N Sarwar, Global Head of Population Research and CVD Genetics
Sanofi: Dr A Plump, Deputy Head of Research and Translational Medicine.
2) NHS, other healthcare providers, policy makers
Although the UK recently introduced a universal national CVD screening programme (NHS Health Check) for adults aged 40-74 years with an expected cost of £2 billion for the initial 5 years, it is acknowledged that many of its details have not been founded on robust evidence and could be optimised (or even re-designed) with emergence of new data.
More generally, there are diverse (and often divergent) guidelines from international bodies about optimum approaches to CVD risk screening, partly because of the limitations in the underpinning epidemiological studies.
Our results should contribute to screening policy because:
-we are closely engaged with translational initiatives of the UK NIHR, eg: JD is the leader of the Population Science theme of the NIHR Cambridge Biomedical Research Centre and of the stroke biomarkers theme of the NIHR Healthcare Technology Cooperative awarded to Cambridge in 2012.
-our previous results have influenced CVD screening guidelines in the USA (eg, AHA / American College of Cardiology) and in Europe (eg, European Society of Cardiology)
-we are contributing to EU initiatives in CVD risk screening as part of EC-FP7.
1) Industry
Our research will directly address three inter-related issues underlying the high rate of failure in medicines development: a) identification of new therapeutic targets b) validation of proposed therapeutic targets and c) stratified approaches to test new agents.
Our findings should feed swiftly into senior R&D decision-making, both at pharmaceutical companies and small and medium-sized enterprises in the biotechnology sector, because:
-industry partners (Merck, Novartis, Pfizer) have co-funded genetic assays for our 100,000-person consortium on a pre-competitive basis, and they will follow the results closely because we have regular meetings and other mechanisms in place (see Pathways to Impact)
-we will continue to work closely with industry to hasten medicines development, exemplified by establishment of the Pfizer-Cambridge Centre for CVD Genomics in our department in 2011 (which has attracted 2 MRC CASE industrial PhD awards and NIHR co-funding)
-we have regular opportunities to engage with senior industry decision-makers, eg: the CEU has strategic collaborations with several industry partners. As noted above, JD is on the international scientific advisory boards of pharmaceutical and biotechnology companies.
The enthusiasm of industry for our proposal is demonstrated by the attached letters of support from:
Merck: Dr M Mendelsohn, Global Franchise Head, Atherosclerosis and CVD, and Dr D Bloomfield, Global Head of CVD Discovery
Novartis: Dr L Letvak, Global Development Franchise Head, Critical Care, and Dr D Keefe, Global Program Head, Lipids
Pfizer: Dr T Rolph, Chief Scientific Officer, Global Cardiovascular Franchise, and Dr N Sarwar, Global Head of Population Research and CVD Genetics
Sanofi: Dr A Plump, Deputy Head of Research and Translational Medicine.
2) NHS, other healthcare providers, policy makers
Although the UK recently introduced a universal national CVD screening programme (NHS Health Check) for adults aged 40-74 years with an expected cost of £2 billion for the initial 5 years, it is acknowledged that many of its details have not been founded on robust evidence and could be optimised (or even re-designed) with emergence of new data.
More generally, there are diverse (and often divergent) guidelines from international bodies about optimum approaches to CVD risk screening, partly because of the limitations in the underpinning epidemiological studies.
Our results should contribute to screening policy because:
-we are closely engaged with translational initiatives of the UK NIHR, eg: JD is the leader of the Population Science theme of the NIHR Cambridge Biomedical Research Centre and of the stroke biomarkers theme of the NIHR Healthcare Technology Cooperative awarded to Cambridge in 2012.
-our previous results have influenced CVD screening guidelines in the USA (eg, AHA / American College of Cardiology) and in Europe (eg, European Society of Cardiology)
-we are contributing to EU initiatives in CVD risk screening as part of EC-FP7.
Organisations
- University of Cambridge (Lead Research Organisation)
- University of Lubeck (Collaboration)
- National Heart Foundation of Bangladesh (Collaboration)
- Biogen Idec (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- Chinese Academy of Medical Sciences (CAMS) (Collaboration)
- Massachusetts General Hospital (Collaboration)
- IInstitute for Medical Research (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- NHS Blood and Transplant (NHSBT) (Collaboration)
- Bangabandhu Sheikh Mujib Medical University (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) (Collaboration)
- Novartis (Collaboration)
- University of Dundee (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- MERCK (Collaboration)
- Go T2D Consortium (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- SomaLogic (Collaboration)
- SWANSEA UNIVERSITY (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- Ministry of Health (Collaboration)
- Pfizer Global R & D (Collaboration)
- International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) (Collaboration)
- QUEEN MARY UNIVERSITY OF LONDON (Collaboration)
- Baker IDI Heart and Diabetes Institute (Collaboration)
- UNIVERSITY OF ABERDEEN (Collaboration)
- Global Lipids Genetic Consortium (GLGC) (Collaboration)
- Brainshake (Collaboration)
- International Medical University (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF LEICESTER (Collaboration)
- Institute of Epidemiology Disease Control And Research (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- AstraZeneca (United Kingdom) (Collaboration)
- Central European University (Collaboration)
- National Heart Institute (Collaboration)
- Karolinska Institute (Project Partner)
- Icelandic Heart Association (Project Partner)
- University of Copenhagen (Project Partner)
- University College London (Project Partner)
- University of Leicester (Project Partner)
- University of Bristol (Project Partner)
- University of Glasgow (Project Partner)
- Wellcome Sanger Institute (Project Partner)
- Imperial College London (Project Partner)
- Broad Institute (Project Partner)
- University of Oxford (Project Partner)
- Queen's University Belfast (Project Partner)
- MRC Centre Cambridge (Project Partner)
Publications
Skaaby T
(2019)
Association of alcohol consumption with allergic disease and asthma: a multi-centre Mendelian randomization analysis.
in Addiction (Abingdon, England)
Britton A
(2017)
The protective effects of moderate drinking: lies, damned lies, and selection biases?
in Addiction (Abingdon, England)
Knott CS
(2018)
The stability of baseline-defined categories of alcohol consumption during the adult life-course: a 28-year prospective cohort study.
in Addiction (Abingdon, England)
Lannelongue L
(2021)
Green Algorithms: Quantifying the Carbon Footprint of Computation.
in Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Glisic M
(2018)
Associations between Phytoestrogens, Glucose Homeostasis, and Risk of Diabetes in Women: A Systematic Review and Meta-Analysis.
in Advances in nutrition (Bethesda, Md.)
Fermont JM
(2021)
Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease.
in Age and ageing
Chowdhury R
(2015)
Invited commentary: dietary polyunsaturated Fatty acids and chronic systemic inflammation--a potentially intriguing link.
in American journal of epidemiology
Paige E
(2018)
Landmark Models for Optimizing the Use of Repeated Measurements of Risk Factors in Electronic Health Records to Predict Future Disease Risk.
in American journal of epidemiology
Smith GC
(2014)
Correcting for optimistic prediction in small data sets.
in American journal of epidemiology
| Guideline Title | ACC/AHA Guideline on the Assessment of Cardiovascular Risk |
| Description | ACC/AHA Guideline on the Assessment of Cardiovascular Risk |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Description | ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical reviews |
| Impact | Atherosclerotic CVD is the leading cause of death for both men and women in the United States.3 It is estimated that if all forms of major CVD were eliminated, life expectancy would rise by almost 7 years.4 Coronary heart disease (CHD) has a long asymptomatic latent period, which provides an opportunity for early preventive interventions. One aim of this guideline is to provide an evidence-based approach to risk assessment in an effort to lower this high burden of coronary deaths in asymptomatic adults. |
| URL | https://www.ahajournals.org/doi/full/10.1161/CIR.0b013e3182051bab |
| Description | Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in other policy documents |
| Description | COMPARE study |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Evidence from the COMPARE study has been key to reducing rates of anaemia among blood donors by convincing NHS Blood and Transplant (NHSBT) to introduce a new approach to pre-donation screening of donor haemoglobin across the entire national blood service in England in 2018. Following presentations and written submissions to the NHSBT Board, NHSBT acted swiftly on the study's two key recommendations. First, they replaced their previously used test with the finger-prick test that had been found in the study to be more accurate - capillary HemoCue®. Second, they fine-tuned ("re-calibrated") the copper sulphate test to enhance its accuracy. As a direct result of these changes, about 100 blood donors each day, or ~30,000 donors every year, are estimated to be saved from avoidable anaemia and potential iron deficiency. As iron deficiency can cause symptoms such as tiredness, shortness of breath, and palpitations, these are significant benefits for donors - who generously give blood to help others. A further related impact of this research has been to avoid potential reputational and financial damage to NHSBT. This could have arisen if NHSBT had gone ahead, without evaluation, with adopting non-invasive light-shining methods to screen haemoglobin levels of donors. Though these methods were used in blood services in Bavaria, Ireland and Spain, they were later found to perform poorly, leading donors to develop avoidable anaemia by being bled when their iron stores were low. The Irish Blood Transfusion Service had to suspend blood donations for a period and face legal action from, and provide financial compensation to, donors. By contrast, the reliable evidence from COMPARE evidence guided NHSBT to avoid spectrometry methods. COMPARE showed that these methods were insufficiently accurate, especially among people of different ethnicities and skin colour types, and were unsuitable for blood services in countries with a large and ethnically diverse pool of donors such as the UK. |
| URL | https://onlinelibrary.wiley.com/doi/10.1111/tme.12750 |
| Description | Citation of published protocol manuscript |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical reviews |
| Description | Citation of published protocol manuscript |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in other policy documents |
| Impact | We have influenced international cardiovascular guidelines through evaluation of the incremental value of assessing established and emerging risk factors for risk assessment, including inflammation biomarkers (NEJM 2012), lipids and lipoproteins (JAMA 2012, Lancet 2010), adiposity measures (Lancet 2011), and carotid ultrasound (Lancet 2012). |
| Description | ERFC (119) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical reviews |
| Impact | The Emerging Risk Factors Collaboration (ERFC) has helped optimise approaches to CVD risk assessment by: 1) quantifying the incremental predictive value provided by assessment of risk factors 2) evaluating the independence of associations between risk factors and CVD and 3) addressing uncertainties related to practical aspects of screening. Publications from the ERFC have been cited by nine guideline statements: 2010: European Atherosclerosis Society (EAS) Consensus Panel on lipoprotein(a) in cardiovascular disease. 2010: American College of Cardiology Foundation / American Heart Association (ACCF / AHA) guideline for assessment of cardiovascular risk in asymptomatic adults 2011: European Society of Cardiology and European Atherosclerosis Society (ESC / EAS) Guidelines for the management of dyslipidaemias 2011: American Heart Association statement on Triglycerides and cardiovascular disease 2011: American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan 2011: US National Lipid Association expert advice 2012: Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult 2012: European Society of Cardiology (ESC) and Other Societies Guidelines on cardiovascular disease prevention in clinical practice 2012: Endocrine society (co-sponsored by the AHA and the European Society of Endocrinology). Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. |
| Description | ERFC - influenced training of practioners or researchers |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | ERFC - major lipids |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | The ERFC paper on major lipids has been cited in the 2011 ESC / EAS Guidelines for the management of dyslipidaemias, in the 2012 ESC Guidelines, the 2011 American Association of Clinical Endocrinologists Medical Guidelines, and the 2011 AHA Statement on Triglycerides and cardiovascular disease. The ERFC publication on the causal relevance of triglyceride-related pathways to coronary disease has been cited in the following guidelines to support the rationale for diagnosis and treatment of hypertriglyceridaemia: the 2012 Endocrine Society Clinical Practice Guideline, the 2011 ESC / EAS Guidelines for the management of dyslipidaemias, and the 2011 AHA Statement on Triglycerides and cardiovascular disease. |
| Description | European Guidelines on cardiovascular disease prevention in clinical practice |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical reviews |
| Impact | N/A |
| Description | Helped to define genetic and biological determinants of lipid and inflammatory related markers |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | INTERVAL study |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | The INTERVAL study provided NHS Blood and Transplant with the first data from a randomised trial of the effects of different blood donation intervals. The quantitative data produced from INTERVAL (and published in The Lancet) include data on the amount of blood collected from donors and the health and well being of blood donors and will inform NHSBT policy on blood donation strategies and policy. |
| Description | Lipoprotein(a) as a cardiovascular risk factor: current status |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical reviews |
| Impact | We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction. |
| Description | LpPLA2 Studies Collaboration |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Successfully embedded research protocols within routine framework of National Blood Service |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Training in the analysis of individual participant data from multiple studies |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Description | Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical reviews |
| Impact | Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically appraise evidence for elevated levels of triglyceride-rich lipoproteins (TRLs) and low levels of high-density lipoprotein cholesterol (HDL-C) as cardiovascular risk factors, and (ii) to advise on therapeutic strategies for management. Current evidence supports a causal association between elevated TRL and their remnants, low HDL-C, and cardiovascular risk. This interpretation is based on mechanistic and genetic studies for TRL and remnants, together with the epidemiological data suggestive of the association for circulating triglycerides and cardiovascular disease. For HDL, epidemiological, mechanistic, and clinical intervention data are consistent with the view that low HDL-C contributes to elevated cardiovascular risk; genetic evidence is unclear however, potentially reflecting the complexity of HDL metabolism. The Panel believes that therapeutic targeting of elevated triglycerides (= 1.7 mmol/L or 150 mg/dL), a marker of TRL and their remnants, and/or low HDL-C (<1.0 mmol/L or 40 mg/dL) may provide further benefit. The first step should be lifestyle interventions together with consideration of compliance with pharmacotherapy and secondary causes of dyslipidaemia. If inadequately corrected, adding niacin or a fibrate, or intensifying LDL-C lowering therapy may be considered. Treatment decisions regarding statin combination therapy should take into account relevant safety concerns, i.e. the risk of elevation of blood glucose, uric acid or liver enzymes with niacin, and myopathy, increased serum creatinine and cholelithiasis with fibrates. These recommendations will facilitate reduction in the substantial cardiovascular risk that persists in patients with cardiometabolic abnormalities at LDL-C goal. |
| Description | Academic Alliance Astrazeneca uk limited centre for genomics research |
| Amount | £480,000 (GBP) |
| Funding ID | RG90583 |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 08/2022 |
| Description | Association between personal exposure to air pollution and adverse health consequences in South |
| Amount | £15,000 (GBP) |
| Funding ID | RG85685 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 03/2017 |
| Description | BHF CoE funding for James Peters |
| Amount | £84,915 (GBP) |
| Funding ID | RG68639 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2016 |
| End | 11/2017 |
| Description | BHF CoE funding for Jonathan Evans |
| Amount | £54,676 (GBP) |
| Funding ID | RG68639 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2017 |
| Description | BHF CoE funding for Lisa Schmunk |
| Amount | £115,759 (GBP) |
| Funding ID | RG68639 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 03/2019 |
| Description | BHF CoE funding for Parsa Akbari |
| Amount | £115,759 (GBP) |
| Funding ID | RG68639 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | BHF, Centre of Excellence - Pump Priming (A Butterworth) |
| Amount | £50,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 12/2015 |
| Description | BHF, Centre of Excellence - Pump Priming (A Wood) |
| Amount | £49,813 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 03/2019 |
| Description | BHF, Centre of Excellence - Pump Priming (D Freitag) |
| Amount | £47,443 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 03/2019 |
| Description | BHF, Centre of Excellence - Pump Priming (D Paul) |
| Amount | £45,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 12/2017 |
| Description | BHF, Centre of Excellence - Pump Priming (E Di Angelantonio) |
| Amount | £49,050 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 07/2016 |
| Description | BHF, Centre of Excellence - Pump Priming (E Harshfield) |
| Amount | £49,950 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 04/2016 |
| Description | BHF/Turing Cardiovascular Data Science Awards - Astle |
| Amount | £79,671 (GBP) |
| Funding ID | BDCSA-100024 |
| Organisation | Alan Turing Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 07/2020 |
| Description | BHF/Turing Cardiovascular Data Science Awards - Wood |
| Amount | £91,414 (GBP) |
| Funding ID | BDCSA-100005 |
| Organisation | Alan Turing Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2020 |
| Description | Biogen |
| Amount | £622,283 (GBP) |
| Organisation | Biogen |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | Biogen |
| Amount | £140,000 (GBP) |
| Organisation | Biogen Idec |
| Sector | Private |
| Country | United States |
| Start | 06/2015 |
| End | 06/2016 |
| Description | Biomedical Research Centre grant - Cardiovascular Theme |
| Amount | £463,767 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2012 |
| End | 03/2017 |
| Description | Biomedical Research Centre grant - Population Science Theme |
| Amount | £1,365,496 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2012 |
| End | 03/2017 |
| Description | Blood Transplant Research Unit (NIHR - BTRU) |
| Amount | £4,099,619 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 09/2020 |
| Description | British Heart Foundation for Philippe Ghilcrist |
| Amount | £93,850 (GBP) |
| Funding ID | RG68639 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 03/2019 |
| Description | Cambridge Biomedical Research Centre |
| Amount | £114,000,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 03/2022 |
| Description | Cambridge alliance to protect Bangladesh from long0term environmental hazards |
| Amount | £7,946,901 (GBP) |
| Funding ID | MR/P02811X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 12/2021 |
| Description | Defining the biological basis of Staphylococcus aureus carriage |
| Amount | £2,341,255 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2023 |
| Description | ECH2020 Societal Challenge - TRANSPOSE |
| Amount | € 549,478 (EUR) |
| Funding ID | 738145 |
| Organisation | European Commission |
| Department | Consumer, Health and Food Executive Agency |
| Sector | Academic/University |
| Country | Luxembourg |
| Start | 09/2017 |
| End | 02/2020 |
| Description | HDRUK |
| Amount | £30,000,000 (GBP) |
| Organisation | Health Data Research UK |
| Sector | Private |
| Country | United Kingdom |
| Start | 04/2018 |
| Description | IMI2 - Big Data for better Hearts |
| Amount | £343,723 (GBP) |
| Funding ID | RG87033 |
| Organisation | European Commission |
| Department | Innovative Medicines Initiative (IMI) |
| Sector | Public |
| Country | Belgium |
| Start | 06/2017 |
| End | 05/2021 |
| Description | Improving Donor Health (NHSBT) |
| Amount | £299,000 (GBP) |
| Funding ID | WP13-02 |
| Organisation | NHS England |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2014 |
| End | 03/2016 |
| Description | Industrial Strategy PhD Studentship MRC DTP 2018 - Loic Lannelongue |
| Amount | £84,680 (GBP) |
| Funding ID | MR/N013433/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 03/2022 |
| Description | Industrial Strategy PhD Studentship MRC DTP 2018 - Tao Jiang |
| Amount | £84,680 (GBP) |
| Funding ID | MR/S502443/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 03/2022 |
| Description | Isaac Newton Trust / Wellcome Trust ISSF / University of Cambridge Joint Research Grant Scheme |
| Amount | £80,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2016 |
| Description | NIHR Senior Investigator |
| Amount | £45,000 (GBP) |
| Funding ID | NF-SI-0617-10113 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2021 |
| Description | NIHR Senior Investigator Award |
| Amount | £45,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Programme Grant |
| Amount | £2,498,808 (GBP) |
| Funding ID | RG/18/13/33946 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 12/2023 |
| Description | RCUK Innovation / Rutherford Fund Fellowships |
| Amount | £451,154 (GBP) |
| Funding ID | MR/S004068/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2021 |
| Description | RCUK Innovation / Rutherford Fund Fellowships |
| Amount | £328,721 (GBP) |
| Funding ID | MR/S003746/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 02/2021 |
| Description | Senior Investigator Grant |
| Amount | £65,000 (GBP) |
| Organisation | Cambridgeshire and Peterborough Clinical Commissioning Group |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2019 |
| Description | Support to enhance phenotyping in the NIHR/NHSBT INTERVAL Bioresource |
| Amount | £53,556 (GBP) |
| Funding ID | RG86292 |
| Organisation | Cambridge University Hospitals NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 03/2017 |
| Description | THE MALAYSIAN ACUTE VASCULAR EVENTS RISK (MAVERIK) STUDY |
| Amount | £400,000 (GBP) |
| Funding ID | RG85814 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2018 |
| Description | USING GENOMICS TO ANTICIPATE CONSEQUENCES OF LIPOPROTEIN(A)-LOWERING: IMPLICATIONS FOR PHASE3 CARDIOVASCULAR OUTCOMES TRIALS |
| Amount | £344,886 (GBP) |
| Funding ID | RG91975 |
| Organisation | Novartis |
| Department | Novartis Pharmaceuticals UK Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 08/2018 |
| Description | Using Genetics to explore the pathophysiology of Cerebral Small Vessel Disease |
| Amount | £94,369 (GBP) |
| Funding ID | RG83983 |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2021 |
| Title | BELIEVE Mirpur, Bauniabadh and Matlab Samples |
| Description | Collection of blood and nail samples from the BELIEVE (BangladEsh Longitudinal Investigation of Emerging Vascular and Non-Vascular Events) Study across three settings; Mirpur (urban), Bauniabadh (urban slum) and Matlab (rural). These three study sites are managed in collaboration with three Bangladeshi partner institutions; the National Heart Foundation, Bangabandhu Sheikh Mujib Medical University and the International Centre for Diarrhoeal Disease Research, Bangladesh. This study aims to recruit up to 150,000 community-based individuals (age >5 years) through a household survey to ensure maximum and generalisable participation, particularly from individuals with shared environmental and genetic background. The key objectives of the BELIEVE prospective cohort study are to create a re-callable population and bio-resource involving a general South Asian population to: (1) enable genetic discovery using diverse phenotypes (particularly those related to nutrition such as anaemia, infection, or environment-related aspects such as air and toxic metal pollution), causal evaluation and functional genomics; (2) assess reliably the roles of established and unique locally-relevant risk factors on incident NCDs such as cardiovascular, cancer, diabetes and kidney diseases (ascertained by clinical records and standardised validation); (3) help study discrepant risk factor patterns unique to this population (eg, unusually high tobacco usage, lowest average body mass index, highest physical inactivity rates) over time, in various age groups as a life-course approach; and their heritability; and (4) create a well-characterised population base to set-up innovative and cost-effective behaviour modification and pharmaceutical interventions, suitable from a South-Asian context. |
| Type Of Material | Biological samples |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | None yet, samples and data still being collected and analysed. |
| Title | BRAVE |
| Description | Collection of biological samples from Bangladesh Risk of Acute Vascular Events (BRAVE) study: Commenced in 2011, BRAVE is being implemented locally in collaboration with National Institute of Cardiovascular Disease Bangladesh, and Chronic Non-Communicable Diseases Unit of icddr,b. As of 2015, BRAVE has already recruited over 6000 first-ever myocardial infarction cases and 6000 healthy controls from capital Dhaka city. Information and biological specimen routinely collected include data using a 400-item questionnaire, physical measurements, blood, toe-nail and extracted DNA samples from all participants. The main objectives of this study are to: •assess the role of potential CVD risk factors (highly prevalent in Bangladeshis) that are yet to be characterized in detail, including: long-term arsenic and other toxic metal contaminations (both separately and in combination), indigenous tobacco consumption; sub-optimal nutrition and genetic variation. •estimate the impact of modifiable conventional vascular risk factors (eg, smoking, history of hypertension, diabetes, physical inactivity, obesity, lipid fractions) on vascular disease in Bangladesh. •evaluate the important local lifestyle, socioeconomic and nutritional exposures on CVD risk, such as diet (eg, local intake patterns of various oil, spices, dairy and fish) and different socio-economic groups; •collect reliable information on knowledge, perception and practice to prevent CVD among participants in order to better understand public health awareness of vascular disease in Bangladesh; and •collect detailed information on the economic burden of CVD events in Bangladesh better understand health economic impact of vascular disease in Bangladesh. |
| Type Of Material | Biological samples |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | Publications |
| Title | COMPARE |
| Description | COMPARE is a study of 30,000 English blood donors set up to determine for NHS Blood and Transplant the most effective way of measuring haemaglobin levels in blood donors. Additionally, participants in the study have consented to have the blood samples used in research and data from genetic and biomarker assays and through linkage with electronic health records will be used across a range of research projects. |
| Type Of Material | Biological samples |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | No impact yet. |
| URL | http://www.comparestudy.org.uk/about-the-study/ |
| Title | Database |
| Description | The clinical phenotype database is also being expanded to stroke outcomes (~9,000 incident cases), rather than just coronary disease, adding further value to the initial investment. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2012 |
| Provided To Others? | Yes |
| Impact | N/A |
| Title | EPIC-Heart Assays |
| Description | Assays have now been completed in all EPIC-Heart participants on the following phenotypes: - 22 clinical chemistry biomarkers - 210,000 genetic variants - a further 450,000 genetic variants - a panel of 37 fatty acids Assays are near completion in these participants for vitamins C and D, a panel of 6 carotenoids and telomere length. These assays are also being extended to stroke cases identified under the FP7 funded project, EPIC-CVD, adding further value to the EPIC-Heart project. |
| Type Of Material | Physiological assessment or outcome measure |
| Year Produced | 2012 |
| Provided To Others? | Yes |
| Impact | N/A |
| Title | EPIC-Heart database |
| Description | Data have been collected and harmonised on >25,000 individuals |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2012 |
| Provided To Others? | No |
| Impact | No impact as yet |
| Title | Emerging Risk Factors Collaboration database |
| Description | A database has been created of harmonised individual participant data records from over 2 million individuals |
| Type Of Material | Improvements to research infrastructure |
| Provided To Others? | No |
| Impact | Published article PMID: 19903920 |
| URL | http://europepmc.org/abstract/MED/19903920 |
| Title | Emerging Risk Factors Collaboration statistical methods |
| Description | Several novel statistical methods have been developed to enable maximal exploitation of the Emerging Risk Factors Collaboration database. |
| Type Of Material | Improvements to research infrastructure |
| Provided To Others? | No |
| Impact | Publication of article PMID: 19903920 |
| URL | http://europepmc.org/abstract/MED/19903920 |
| Title | INTERVAL Bioresource |
| Description | INTERVAL is a randomised controlled trial in up to 50,000 whole-blood donors recruited at 25 locations across England. Participants are involved in a two-year intervention during which they are invited to give blood either at usual donation intervals or more often. The primary aim of the intervention is to establish whether donors can safely and acceptably give blood more often than is now collected by NHS Blood and Transplant. A further aim of INTERVAL is to create a national epidemiological bioresource, including a recall-by-genotype (phenotype) resource, which will enable detailed study of the health of blood donors and broader public health and biomedical issues. Participant recruitment commenced in June 2012. Our target of 50,000 study participants was reached two years later, in June 2014. Participants have consented to: use of their data and biological samples for a wide range of analyses, invitation to further biomedical studies, and long-term linkage to e-health records. Funding that has been awarded from NHSBT and NIHR will allow the study of the following factors in 50,000 participants i) extended haematological profile (>200 parameters) ii) lifestyle profiling, including assessment of smoking, alcohol consumption, dietary intake, and, in large subsets, monitoring of physical activity through the use of worn accelerometry devices; (iii) cognitive function traits related to different domains of mental function and well-being; and (iv) linkage with e-health records, eg, various morbidity registers, hospital discharge records (v) a novel gene array containing 850,000 single nucleotide variants (SNVs), which includes many functional SNVs and a GWAS scaffold to deliver imputation of ~20 million variants; (vi) ~200 candidate biomarkers related to haematological traits and other pathways for a wide range of disease processes (eg, liver and renal function; autoimmunity; hormonal status). |
| Type Of Material | Biological samples |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | Serum samples collected during the study have been used to measure the levels of ferritin in participants. DNA has been used in a genome-wide association study of haemoglobin concentration and related parameters, and genotyping of the HFE gene. |
| Title | Methods |
| Description | To allow the assessment of risk prediction in a multi-centre case-cohort study, novel statistical methods have been developed at the EPIC-Heart Coordinating Centre |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | A Publication: "Derivation and assessment of risk prediction models using case-cohort data". Sanderson J, Thompson SG, White IR, Aspelund T, Pennells L. BMC Med Res Methodol. 2013 Sep 13;13(1):113 |
| Title | PROMIS |
| Description | Collection of samples from The Pakistan Risk of Myocardial Infarction Study (PROMIS): 35,000 participants have been recruited for this study aged 30-80 years (both male and female) with a first-ever confirmed myocardial infarction (MI) and "frequency-matched" controls (on age and sex) free from cardiovascular or other chronic diseases. Information collected on each participant includes a detailed questionnaire (including extensive information on lifestyle and dietary habits tailored to local dietary patterns), blood samples (including serum, plasma and whole blood) and DNA extracted from white blood cells. Samples are transported to the core laboratory at the Department of Public Health and Primary Care, University of Cambridge, for long-term storage and subsequent genetic and biochemical analyses. PROMIS will help to identify and understand the separate and combined influences of genetic and major lifestyle factors on the risk of MI, and to help elucidate intermediate causal pathways. Investigations underway in the available cases and controls already collected include assessment of candidate gene, biochemical, dietary and lifestyle influences as well as genome wide association studies. We are exploring collection of more detailed information in a sizeable subset of participants to enable more detailed investigations, such as the establishment of cell-lines and studies of gene expression (using RNA samples from monocytes, lipid biopsies and other sources). |
| Type Of Material | Biological samples |
| Year Produced | 2012 |
| Provided To Others? | Yes |
| Impact | Publications |
| Title | Quantifying net benefits |
| Description | A framework for quantifying net benefits of alternative prognostic models |
| Type Of Material | Improvements to research infrastructure |
| Provided To Others? | No |
| Impact | Publication 21905066 |
| Title | Statistical Methods and databases |
| Description | Dataset of over 40,000 cases of CHD in over 180,000 participants from 47 studies with data on CRP genetic variants, circulating CRP and other biomarkers. Statistical methods for further developing the methodology for Mendelian randomization analyses. |
| Type Of Material | Biological samples |
| Year Produced | 2012 |
| Provided To Others? | No |
| Impact | N/A |
| Title | Statistical programs made freely available to researchers |
| Description | Bespoke statistical programs for the meta-analysis of individual participant data have been made freely available to researchers via the ERFC website |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | N/A |
| URL | http://www.phpc.cam.ac.uk/ceu/research/erfc/stata/ |
| Title | The Lp-PLA2 Studies Collaboration database |
| Description | A database has been created of harmonised individual participant data records from over 110,000 individuals |
| Type Of Material | Improvements to research infrastructure |
| Provided To Others? | No |
| Impact | n/a |
| Title | BELIEVE Mirpur (Urban), Bauniabadh (Urban Slum) and Matlab (Rural) |
| Description | Collection of data from the BELIEVE (BangladEsh Longitudinal Investigation of Emerging Vascular and Non-Vascular Events) Study across three settings; Mirpur (urban), Bauniabadh (urban slum) and Matlab (rural). These three study sites are managed in collaboration with three Bangladeshi partner institutions; the National Heart Foundation, Bangabandhu Sheikh Mujib Medical University and the International Centre for Diarrhoeal Disease Research, Bangladesh. This study aims to recruit up to 150,000 community-based individuals (age >5 years) through a household survey to ensure maximum and generalisable participation, particularly from individuals with shared environmental and genetic background. The key objectives of the BELIEVE prospective cohort study are to create a re-callable population and bio-resource involving a general South Asian population to: (1) enable genetic discovery using diverse phenotypes (particularly those related to nutrition such as anaemia, infection, or environment-related aspects such as air and toxic metal pollution), causal evaluation and functional genomics; (2) assess reliably the roles of established and unique locally-relevant risk factors on incident NCDs such as cardiovascular, cancer, diabetes and kidney diseases (ascertained by clinical records and standardised validation); (3) help study discrepant risk factor patterns unique to this population (eg, unusually high tobacco usage, lowest average body mass index, highest physical inactivity rates) over time, in various age groups as a life-course approach; and their heritability; and (4) create a well-characterised population base to set-up innovative and cost-effective behaviour modification and pharmaceutical interventions, suitable from a South-Asian context. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | None yet, samples and data still being collected and analysed. |
| URL | https://www.capable-bangladesh.org/cohorts/ |
| Title | BRAVE |
| Description | Collection of data from Bangladesh Risk of Acute Vascular Events (BRAVE) study: Commenced in 2011, BRAVE is being implemented locally in collaboration with National Institute of Cardiovascular Disease Bangladesh, and Chronic Non-Communicable Diseases Unit of icddr,b. As of 2015, BRAVE has already recruited over 6000 first-ever myocardial infarction cases and 6000 healthy controls from capital Dhaka city. Information and biological specimen routinely collected include data using a 400-item questionnaire, physical measurements, blood, toe-nail and extracted DNA samples from all participants. The main objectives of this study are to: •assess the role of potential CVD risk factors (highly prevalent in Bangladeshis) that are yet to be characterized in detail, including: long-term arsenic and other toxic metal contaminations (both separately and in combination), indigenous tobacco consumption; sub-optimal nutrition and genetic variation. •estimate the impact of modifiable conventional vascular risk factors (eg, smoking, history of hypertension, diabetes, physical inactivity, obesity, lipid fractions) on vascular disease in Bangladesh. •evaluate the important local lifestyle, socioeconomic and nutritional exposures on CVD risk, such as diet (eg, local intake patterns of various oil, spices, dairy and fish) and different socio-economic groups; •collect reliable information on knowledge, perception and practice to prevent CVD among participants in order to better understand public health awareness of vascular disease in Bangladesh; and •collect detailed information on the economic burden of CVD events in Bangladesh better understand health economic impact of vascular disease in Bangladesh. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | Publications |
| Title | CARDIoGRAMplusC4D consortium |
| Description | Genetic consortium |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 |
| Title | COMPARE |
| Description | COMPARE is a study of 30,000 English blood donors set up to determine for NHS Blood and Transplant the most effective way of measuring haemaglobin levels in blood donors. Additionally, participants in the study have consented to have the blood samples used in research and data from genetic and biomarker assays and through linkage with electronic health records will be used across a range of research projects. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | In the largest study reporting head-to-head comparisons of four methods to measure haemoglobin prior to blood donation, our results support replacement of NHS Blood and Transplant's (NHSBT) customary method with portable haemoglobinometry. The results from this study directly changed NHSBT practice. https://onlinelibrary.wiley.com/doi/10.1111/tme.12750 |
| URL | http://www.comparestudy.org.uk |
| Title | CRP Collaboration Database |
| Description | Dataset of over 40,000 cases of CHD in over 180,000 participants from 47 studies with data on CRP genetic variants, circulating CRP and other biomarkers. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | No |
| Impact | Publications as listed |
| Title | EPIC-CVD database |
| Description | The EPIC-Heart phenotype database is being expanded to stroke outcomes (~9000 incident cases), rather than just coronary disease, adding further value to the initial investment |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | N/A |
| Title | Emerging Risk Factors Collaboration Database |
| Description | A database has been created of harmonised individual participant data records from over 2 million individuals |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | Published article PMID: 19903920 |
| URL | http://europepmc.org/abstract/MED/19903920 |
| Title | EpiCov Research Database |
| Description | The EpiCov database contains de-identified patient and NHS staff data from the Cambridge University Hospitals NHS Foundation Trust (CUH) Electronic Health Record systems, including scan images and laboratory results. The database will include routinely collected information about patients diagnosed with COVID-19 or suspected of having COVID-19, and staff who have been tested for COVID-19. It will also include information about a large number of control patients who do not have a diagnosis of COVID-19. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | This will allow comparisons of patients with and without COVID-19 infection who have similar symptoms to see if there are any important differences that might help us understand the best way to prevent, diagnose and treat COVID-19 infection. Thousands of patients need to be compared to check if any differences found between them are related to age, gender or the season. No direct personal identifiers (such as name, date of birth, contact details, hospital or NHS number) will be included in the database. All information will be extracted and de-identified through an automated process by the CUH Clinical Informatics Team who process patient data as part of their job role. The database will facilitate a variety of research related to COVID-19 aimed at improving health, treatment or services. Research will include large data studies using advanced methods of analysis, such as machine learning, with the aim of learning about how to predict patient outcomes and the best way to treat patients based on their clinical information. The EpiCov database will both enable local researchers to use the Electronic Health Record resource for important research, and also allow CUH to contribute well-curated data to other national and international COVID-19 projects and databases. |
| URL | https://cambridgebrc.nihr.ac.uk/expandables/data-lay-summary-1/ |
| Title | Exome Chip Consortium |
| Description | Exome chip consortium |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | N/A |
| Title | INTERVAL Bioresource |
| Description | INTERVAL is a randomised controlled trial in up to 50,000 whole-blood donors recruited at 25 locations across England. Participants are involved in a two-year intervention during which they are invited to give blood either at usual donation intervals or more often. The primary aim of the intervention is to establish whether donors can safely and acceptably give blood more often than is now collected by NHS Blood and Transplant. A further aim of INTERVAL is to create a national epidemiological bioresource, including a recall-by-genotype (phenotype) resource, which will enable detailed study of the health of blood donors and broader public health and biomedical issues. Participant recruitment commenced in June 2012. Our target of 50,000 study participants was reached two years later, in June 2014. Participants have consented to: use of their data and biological samples for a wide range of analyses, invitation to further biomedical studies, and long-term linkage to e-health records. Funding that has been awarded from NHSBT and NIHR will allow the study of the following factors in 50,000 participants i) extended haematological profile (>200 parameters) ii) lifestyle profiling, including assessment of smoking, alcohol consumption, dietary intake, and, in large subsets, monitoring of physical activity through the use of worn accelerometry devices; (iii) cognitive function traits related to different domains of mental function and well-being; and (iv) linkage with e-health records, eg, various morbidity registers, hospital discharge records (v) a novel gene array containing 850,000 single nucleotide variants (SNVs), which includes many functional SNVs and a GWAS scaffold to deliver imputation of ~20 million variants; (vi) ~200 candidate biomarkers related to haematological traits and other pathways for a wide range of disease processes (eg, liver and renal function; autoimmunity; hormonal status). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | Further collaboration, most notably with the Wellcome Trust Sanger Institute |
| URL | http://www.intervalstudy.org.uk/ |
| Title | Large-scale Research Database Established |
| Description | Dataset from >130 studies with over 2.3M individuals and 100,000 cases of cardiovascular disease with information on conventional risk factors for CVD and other circulating biomarkers and lifestyle factors. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | N/A |
| Title | MAVERIK |
| Description | MAVERIK is a case-control study of acute vascular events in Malaysia. 2,500 cases and 2,500 control participants are being collected from hospitals across Malaysia. Participants answer questionnaires and provide blood samples which will help the understanding a cardiovascular events, including risk factors specific to Malaysia. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | Publication. |
| Title | Mendelian Randomisation Method |
| Description | Dataset of over 40,000 cases of CHD in over 180,000 participants from 47 studies with data on CRP genetic variants, circulating CRP and other biomarkers. Statistical methods for further developing the methodology for Mendelian randomization analyses. |
| Type Of Material | Data analysis technique |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | N/A |
| Title | Metabochip Consortium |
| Description | Metabochip Consortium database |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | N/A |
| Title | PROMIS |
| Description | Collection of data from The Pakistan Risk of Myocardial Infarction Study (PROMIS): 35,000 participants have been recruited for this study aged 30-80 years (both male and female) with a first-ever confirmed myocardial infarction (MI) and "frequency-matched" controls (on age and sex) free from cardiovascular or other chronic diseases. Information collected on each participant includes a detailed questionnaire (including extensive information on lifestyle and dietary habits tailored to local dietary patterns), blood samples (including serum, plasma and whole blood) and DNA extracted from white blood cells. Samples are transported to the core laboratory at the Department of Public Health and Primary Care, University of Cambridge, for long-term storage and subsequent genetic and biochemical analyses. PROMIS will help to identify and understand the separate and combined influences of genetic and major lifestyle factors on the risk of MI, and to help elucidate intermediate causal pathways. Investigations underway in the available cases and controls already collected include assessment of candidate gene, biochemical, dietary and lifestyle influences as well as genome wide association studies. We are exploring collection of more detailed information in a sizeable subset of participants to enable more detailed investigations, such as the establishment of cell-lines and studies of gene expression (using RNA samples from monocytes, lipid biopsies and other sources). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | Publications |
| Title | PhenoScanner |
| Description | Mendelian Randomisation (MR) Catalogue is a curated database of publicly available results from large-scale genetic association studies. This tool aims to facilitate "phoneme scans", the cross-referencing of genetic variants with many phenotypes, to help aid understanding of disease pathways and biology as well as inform MR studies. The catalogue currently contains over 300 million association results and over 10 million unique genetic variants, mostly single nucleotide polymorphisms. It is accompanied by a web-based tool that queries the database for associations with user-specified variants, providing results aligned according to the alleles of each input variant. The tool provides the option of searching for trait associations with proxies of the input variants, calculated using the European samples from 1000 Genomes phase 3. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | MR Catalogue has been used extensively within the Cardiovascular Epidemiology Unit, University of Cambridge, and has been used in a few high profile papers currently under review. We recently released MR Catalogue to the wider scientific community and we have had over 1,000 usages of the website already. We anticipate that this tool will be widely used within the genetics community. In 2019, PhenoScanner v2 was released. |
| URL | http://www.phenoscanner.medschl.cam.ac.uk/ |
| Title | Statistical Methods and Database |
| Description | Dataset from >130 studies with over 2.3M individuals and 100,000 cases of cardiovascular disease with information on conventional risk factors for CVD and other circulating biomarkers and lifestyle factors. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | N/A |
| Title | Statistical methodology (optimistic prediction) |
| Description | Correcting for Optimistic Prediction in Small Data Sets |
| Type Of Material | Data analysis technique |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | N/A |
| Description | AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The collaboration with AstraZeneca has two parts: 1) Using genomic and molecular information in the INTERVAL study to inform AstraZeneca's therapeutic target prioritisation. We aim: a) To systematically mine CEU's datasets for association signals in or near genes relevant to AZ targets to enable the creation of genetic scores that mimic therapeutic intervention b) To validate informative scores by identifying associations with relevant "positive control" outcomes, such as diseases, molecular biomarkers or traits. c) To assess the association of informative scores on a wide range of molecular and clinical outcomes to inform drug efficacy, on-target safety and/or alternative indications. 2) Whole blood RNA sequencing in the INTERVAL study: we will validate whole blood mRNA sequencing from INTERVAL donors as a robust and scalable 'omics layer to add to the detailed genomic and molecular phenotyping that exists in these participants. |
| Collaborator Contribution | Funding support of £480,000 and provided a list of high-priority therapeutic targets, with primary indications of interest, and supporting information across a number of domains of biological and clinical science. |
| Impact | Presented results at the AstraZeneca Centre for Genomics Research Annual Collaborators in July 2018. IGMM Seminar University of Edinburgh (Adam Butterworth) Received data from RNA sequencing of 4000 samples |
| Start Year | 2017 |
| Description | BELIEVE |
| Organisation | National Heart Foundation of Bangladesh |
| Country | Bangladesh |
| Sector | Charity/Non Profit |
| PI Contribution | Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership. |
| Collaborator Contribution | Conduct of the protocol, use of resources and sample/data transport |
| Impact | N/A - commenced 2016 |
| Start Year | 2016 |
| Description | BRAVE |
| Organisation | International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) |
| Country | Bangladesh |
| Sector | Public |
| PI Contribution | Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership. |
| Collaborator Contribution | Conduct of the protocol, use of resources and sample/data transport |
| Impact | Publications |
| Start Year | 2010 |
| Description | Biogen |
| Organisation | Biogen Idec |
| Country | United States |
| Sector | Private |
| PI Contribution | Scientific expertise; data analysis; provision of samples; development of statistical methodologies; access to dense genotypic and phenotpyic datasets. |
| Collaborator Contribution | Financial and scientific input. |
| Impact | No outcomes yet. |
| Start Year | 2017 |
| Description | CAPABLE - BSMMU |
| Organisation | Bangabandhu Sheikh Mujib Medical University |
| Country | Bangladesh |
| Sector | Academic/University |
| PI Contribution | Intellectual input and scientific direction/coordination to help set up a research cohort to better understand disease and environmental risks in Bangladesh. Coordinating centre for the CAPABLE programme under which this collaboration sits. |
| Collaborator Contribution | Intellectual input and scientific direction/coordination to help set up a research cohort to better understand disease and environmental risks in Bangladesh. Provision of staff, resources, space. |
| Impact | No outputs yet. |
| Start Year | 2017 |
| Description | CAPABLE - IEDCR |
| Organisation | Institute of Epidemiology Disease Control And Research |
| Country | Bangladesh |
| Sector | Public |
| PI Contribution | Intellectual input to the research into environmental and lifestyle risk factors in Bangladesh with respect to non-communicable diseases, as well as the planning and coordination of capacity building and training in the programme. Coordinating centre responsible for the CAPABLE consortium under which this collaboration sits. |
| Collaborator Contribution | Intellectual input to the research into environmental and lifestyle risk factors in Bangladesh with respect to non-communicable diseases, as well as the planning and coordination of capacity building and training in the programme. Provision of space and resources for capacity building elements of the programme. |
| Impact | Not outputs yet. |
| Start Year | 2017 |
| Description | CAPABLE-University College London |
| Organisation | University College London |
| Department | Institute For Global Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Intellectual input and scientific direction/coordination to help set up a work stream on social determinants and better understand disease and environmental risks in Bangladesh. |
| Collaborator Contribution | Intellectual input and scientific direction/coordination to help set up a work stream on social determinants, policy and gender studies to better understand disease and environmental risks in Bangladesh. Supervision of fellows, capacity building. |
| Impact | No outcomes yet |
| Start Year | 2017 |
| Description | CAPABLE-University of Aberdeen |
| Organisation | University of Aberdeen |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Intellectual input and scientific direction/coordination for studying arsenic and other environmental toxic metals. Coordinating centre for analytical analyses in biological and non-biological samples. |
| Collaborator Contribution | Intellectual input and scientific direction/coordination to better understand disease and environmental risks in Bangladesh. Provision of staff, resources, space, capacity building, development of novel analytical methods to study the concentration of toxic metals in biological and non-biological samples. |
| Impact | No outputs yet |
| Start Year | 2017 |
| Description | CARDIoGRAMplusC4D consortium |
| Organisation | Chinese Academy of Medical Sciences (CAMS) |
| Country | China |
| Sector | Academic/University |
| PI Contribution | Coordinating centre |
| Collaborator Contribution | contribution of data and analyses |
| Impact | Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051 |
| Start Year | 2010 |
| Description | CARDIoGRAMplusC4D consortium |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Coordinating centre |
| Collaborator Contribution | contribution of data and analyses |
| Impact | Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051 |
| Start Year | 2010 |
| Description | CARDIoGRAMplusC4D consortium |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Coordinating centre |
| Collaborator Contribution | contribution of data and analyses |
| Impact | Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051 |
| Start Year | 2010 |
| Description | CARDIoGRAMplusC4D consortium |
| Organisation | Queen Mary University of London |
| Department | Barts and The London School of Medicine and Dentistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Coordinating centre |
| Collaborator Contribution | contribution of data and analyses |
| Impact | Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051 |
| Start Year | 2010 |
| Description | CARDIoGRAMplusC4D consortium |
| Organisation | University of Leicester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Coordinating centre |
| Collaborator Contribution | contribution of data and analyses |
| Impact | Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051 |
| Start Year | 2010 |
| Description | CARDIoGRAMplusC4D consortium |
| Organisation | University of Lubeck |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Coordinating centre |
| Collaborator Contribution | contribution of data and analyses |
| Impact | Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051 |
| Start Year | 2010 |
| Description | Exome Chip Consortium |
| Organisation | Harvard University |
| Department | Harvard T.H. Chan School of Public Health |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | coordinating centre |
| Collaborator Contribution | funding, contribution of data and analyses |
| Impact | N/A |
| Start Year | 2012 |
| Description | Exome Chip Consortium |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | coordinating centre |
| Collaborator Contribution | funding, contribution of data and analyses |
| Impact | N/A |
| Start Year | 2012 |
| Description | Exome Chip Consortium |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | coordinating centre |
| Collaborator Contribution | funding, contribution of data and analyses |
| Impact | N/A |
| Start Year | 2012 |
| Description | Exome Chip Consortium |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | coordinating centre |
| Collaborator Contribution | funding, contribution of data and analyses |
| Impact | N/A |
| Start Year | 2012 |
| Description | Exome Chip Consortium |
| Organisation | Pfizer Global R & D |
| Country | United States |
| Sector | Private |
| PI Contribution | coordinating centre |
| Collaborator Contribution | funding, contribution of data and analyses |
| Impact | N/A |
| Start Year | 2012 |
| Description | Exome Chip Consortium |
| Organisation | Queen Mary University of London |
| Department | Barts and The London School of Medicine and Dentistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | coordinating centre |
| Collaborator Contribution | funding, contribution of data and analyses |
| Impact | N/A |
| Start Year | 2012 |
| Description | Exome Chip Consortium |
| Organisation | University of Leicester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | coordinating centre |
| Collaborator Contribution | funding, contribution of data and analyses |
| Impact | N/A |
| Start Year | 2012 |
| Description | Genetic Association Study of Blood Pressure (BP Exome) |
| Organisation | Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) |
| Country | Global |
| Sector | Academic/University |
| PI Contribution | CHD Exome+ consortium jointly led this research project and also contributed samples to the discovery meta-analyses. |
| Collaborator Contribution | ExomeBP and GoT2D Consortia contributed samples for the discovery meta-analyses and CHARGE+ consortium contributed replication samples. |
| Impact | Manuscript under consideration at Nature Genetics |
| Start Year | 2014 |
| Description | Genetic Association Study of Blood Pressure (BP Exome) |
| Organisation | Go T2D Consortium |
| Country | Unknown |
| Sector | Learned Society |
| PI Contribution | CHD Exome+ consortium jointly led this research project and also contributed samples to the discovery meta-analyses. |
| Collaborator Contribution | ExomeBP and GoT2D Consortia contributed samples for the discovery meta-analyses and CHARGE+ consortium contributed replication samples. |
| Impact | Manuscript under consideration at Nature Genetics |
| Start Year | 2014 |
| Description | Global BMI Mortality Collaboration |
| Organisation | Harvard University |
| Department | Harvard T.H. Chan School of Public Health |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | The Global BMI Mortality Collaboration was established to enable valid estimation of associations of overweight and obesity with all-cause mortality across populations in major global regions. The consortium involves data from large individual prospective studies (defined as =100,000 participants recruited at baseline) or large multi-cohort consortia (defined as involving a total of =100,000 participants recruited at baseline). A pre-specified analysis plan for combining individual-participant data from relevant cohorts was agreed among collaborators. |
| Collaborator Contribution | The Global BMI Mortality Collaboration was established to enable valid estimation of associations of overweight and obesity with all-cause mortality across populations in major global regions. The consortium involves data from large individual prospective studies (defined as =100,000 participants recruited at baseline) or large multi-cohort consortia (defined as involving a total of =100,000 participants recruited at baseline). A pre-specified analysis plan for combining individual-participant data from relevant cohorts was agreed among collaborators. |
| Impact | The Global BMI Mortality Collaboration was established to enable valid estimation of associations of overweight and obesity with all-cause mortality across populations in major global regions. The consortium involves data from large individual prospective studies (defined as =100,000 participants recruited at baseline) or large multi-cohort consortia (defined as involving a total of =100,000 participants recruited at baseline). A pre-specified analysis plan for combining individual-participant data from relevant cohorts was agreed among collaborators. |
| Start Year | 2013 |
| Description | Global Lipids Genetics Consortium (GLGC) |
| Organisation | Global Lipids Genetic Consortium (GLGC) |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | CHD Exome+ consortium contributed samples to the discovery meta-analyses. |
| Collaborator Contribution | GLGC Consortium leads this analyses |
| Impact | Manuscript currently being drafted |
| Start Year | 2013 |
| Description | HbF collaboration with University of Oxford |
| Organisation | University of Oxford |
| Department | Department of Plant Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of samples; access to genetic databases; scientific input. |
| Collaborator Contribution | Performing HbF assays; scientific input. |
| Impact | No output yet. |
| Start Year | 2016 |
| Description | IMR Malaysia |
| Organisation | Ministry of Health Malaysia |
| Department | Institute for Medical Research |
| Country | Malaysia |
| Sector | Public |
| PI Contribution | This collaboration led to securing of additional £200000 funding from the Malaysian Academy of Science. We are working closely with the IMR researchers to implement the MAVERIK study. |
| Collaborator Contribution | IMR researchers are contributing to design and implementation of the study. |
| Impact | None so far as the research study is still in progress. |
| Start Year | 2017 |
| Description | INTERVAL |
| Organisation | NHS Blood and Transplant (NHSBT) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We provide scientific leadership and operational support. We are the academic coordinating centre, running the administration and data management of the trial (including the helpline). |
| Collaborator Contribution | NHSBT provide funding and operational support. The University of Oxford provide scientific leadership and operational support. |
| Impact | INTERVAL is a randomised controlled trial in up to 50,000 whole-blood donors recruited at 25 locations across England. Participants are involved in a two-year intervention during which they are invited to give blood either at usual donation intervals or more often. The primary aim of the intervention is to establish whether donors can safely and acceptably give blood more often than is now collected by NHS Blood and Transplant. A further aim of INTERVAL is to create a national epidemiological bioresource, including a recall-by-genotype (phenotype) resource, which will enable detailed study of the health of blood donors and broader public health and biomedical issues. Participant recruitment commenced in June 2012. Our target of 50,000 study participants was reached two years later, in June 2014. Participants have consented to: use of their data and biological samples for a wide range of analyses, invitation to further biomedical studies, and long-term linkage to e-health records. Funding that has been awarded from NHSBT and NIHR will allow the study of the following factors in 50,000 participants i) extended haematological profile (>200 parameters) ii) lifestyle profiling, including assessment of smoking, alcohol consumption, dietary intake, and, in large subsets, monitoring of physical activity through the use of worn accelerometry devices; (iii) cognitive function traits related to different domains of mental function and well-being; and (iv) linkage with e-health records, eg, various morbidity registers, hospital discharge records (v) a novel gene array containing 850,000 single nucleotide variants (SNVs), which includes many functional SNVs and a GWAS scaffold to deliver imputation of ~20 million variants; (vi) ~200 candidate biomarkers related to haematological traits and other pathways for a wide range of disease processes (eg, liver and renal function; autoimmunity; hormonal status). |
| Start Year | 2012 |
| Description | INTERVAL |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We provide scientific leadership and operational support. We are the academic coordinating centre, running the administration and data management of the trial (including the helpline). |
| Collaborator Contribution | NHSBT provide funding and operational support. The University of Oxford provide scientific leadership and operational support. |
| Impact | INTERVAL is a randomised controlled trial in up to 50,000 whole-blood donors recruited at 25 locations across England. Participants are involved in a two-year intervention during which they are invited to give blood either at usual donation intervals or more often. The primary aim of the intervention is to establish whether donors can safely and acceptably give blood more often than is now collected by NHS Blood and Transplant. A further aim of INTERVAL is to create a national epidemiological bioresource, including a recall-by-genotype (phenotype) resource, which will enable detailed study of the health of blood donors and broader public health and biomedical issues. Participant recruitment commenced in June 2012. Our target of 50,000 study participants was reached two years later, in June 2014. Participants have consented to: use of their data and biological samples for a wide range of analyses, invitation to further biomedical studies, and long-term linkage to e-health records. Funding that has been awarded from NHSBT and NIHR will allow the study of the following factors in 50,000 participants i) extended haematological profile (>200 parameters) ii) lifestyle profiling, including assessment of smoking, alcohol consumption, dietary intake, and, in large subsets, monitoring of physical activity through the use of worn accelerometry devices; (iii) cognitive function traits related to different domains of mental function and well-being; and (iv) linkage with e-health records, eg, various morbidity registers, hospital discharge records (v) a novel gene array containing 850,000 single nucleotide variants (SNVs), which includes many functional SNVs and a GWAS scaffold to deliver imputation of ~20 million variants; (vi) ~200 candidate biomarkers related to haematological traits and other pathways for a wide range of disease processes (eg, liver and renal function; autoimmunity; hormonal status). |
| Start Year | 2012 |
| Description | International CHD Genetics Consortium |
| Organisation | Central European University |
| Country | Hungary |
| Sector | Academic/University |
| PI Contribution | The research team have raised funding to assay GWAS, Exome array and CardioMetabochip in most of these participants, brought together the studies and collaborators, collated and harmonised phenotype and clinical data at CEU, coordinated genotyping and data cleaning, formulated and implemented analysis plans. |
| Collaborator Contribution | Provided individual participant data and commented on draft analyses and texts prior to submission of manuscripts for publication |
| Impact | The main outcomes to date are the contribution to discovery of new genetic loci for CHD by subsets of the Consortium. Papers: - IBC 50K CAD Consortium. PLoS Genet. 2011;Sep;7(9):e1002260 (PMID:21966275) - Coronary Artery Disease (C4D) Genetics Consortium. Nat Genet. 2011 Mar 6;43(4):339-44 (PMID:21378988) - The CARDIoGRAMplusC4D Consortium. Nat Genet. 2012 Dec 2 (PMID:23202125) A number of similarly high impact papers are expected to emerge once data from all 100,000 participants have been generated, harmonised and analysed. |
| Start Year | 2010 |
| Description | Lipidomics - MRC-HNR |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Human Nutrition Research Group |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We provided samples from 50,000 participants (whole cohort) from the INTERVAL study for analysis |
| Collaborator Contribution | Analysis of all 50,000 samples in progress - 400 lipid species measured. Assays contributed in kind by MRC-HNR |
| Impact | Data received at regular intervals |
| Start Year | 2015 |
| Description | MAVERIK |
| Organisation | IInstitute for Medical Research |
| Country | Malaysia |
| Sector | Public |
| PI Contribution | Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership. |
| Collaborator Contribution | Funding, protocol design and implementation support; recruitment of participants into case/control study. |
| Impact | None yet. |
| Start Year | 2017 |
| Description | MAVERIK |
| Organisation | International Medical University |
| Country | Malaysia |
| Sector | Academic/University |
| PI Contribution | Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership. |
| Collaborator Contribution | Funding, protocol design and implementation support; recruitment of participants into case/control study. |
| Impact | None yet. |
| Start Year | 2017 |
| Description | MAVERIK |
| Organisation | National Heart Institute |
| Country | Malaysia |
| Sector | Hospitals |
| PI Contribution | Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership. |
| Collaborator Contribution | Funding, protocol design and implementation support; recruitment of participants into case/control study. |
| Impact | None yet. |
| Start Year | 2017 |
| Description | Multi-omics consortium |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | My research team will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, and populations cohorts totalling 80,000 participants that have been densely genotyped and phenotyped and are linked to electronic health records. |
| Collaborator Contribution | Partners will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, infrastructural computing expertise, and populations cohortsthat have been densely genotyped and phenotyped and are linked to electronic health records. |
| Impact | The multi-omics consortium has been awarded £1.1M through HDR UK. |
| Start Year | 2019 |
| Description | Multi-omics consortium |
| Organisation | Swansea University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | My research team will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, and populations cohorts totalling 80,000 participants that have been densely genotyped and phenotyped and are linked to electronic health records. |
| Collaborator Contribution | Partners will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, infrastructural computing expertise, and populations cohortsthat have been densely genotyped and phenotyped and are linked to electronic health records. |
| Impact | The multi-omics consortium has been awarded £1.1M through HDR UK. |
| Start Year | 2019 |
| Description | Multi-omics consortium |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | My research team will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, and populations cohorts totalling 80,000 participants that have been densely genotyped and phenotyped and are linked to electronic health records. |
| Collaborator Contribution | Partners will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, infrastructural computing expertise, and populations cohortsthat have been densely genotyped and phenotyped and are linked to electronic health records. |
| Impact | The multi-omics consortium has been awarded £1.1M through HDR UK. |
| Start Year | 2019 |
| Description | Multi-omics consortium |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | My research team will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, and populations cohorts totalling 80,000 participants that have been densely genotyped and phenotyped and are linked to electronic health records. |
| Collaborator Contribution | Partners will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, infrastructural computing expertise, and populations cohortsthat have been densely genotyped and phenotyped and are linked to electronic health records. |
| Impact | The multi-omics consortium has been awarded £1.1M through HDR UK. |
| Start Year | 2019 |
| Description | Multi-omics consortium |
| Organisation | University of Dundee |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | My research team will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, and populations cohorts totalling 80,000 participants that have been densely genotyped and phenotyped and are linked to electronic health records. |
| Collaborator Contribution | Partners will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, infrastructural computing expertise, and populations cohortsthat have been densely genotyped and phenotyped and are linked to electronic health records. |
| Impact | The multi-omics consortium has been awarded £1.1M through HDR UK. |
| Start Year | 2019 |
| Description | Multi-omics consortium |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | My research team will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, and populations cohorts totalling 80,000 participants that have been densely genotyped and phenotyped and are linked to electronic health records. |
| Collaborator Contribution | Partners will bring scientific domain knowledge, epidemilogical and statistical skills and capacity, infrastructural computing expertise, and populations cohortsthat have been densely genotyped and phenotyped and are linked to electronic health records. |
| Impact | The multi-omics consortium has been awarded £1.1M through HDR UK. |
| Start Year | 2019 |
| Description | NIHR BTRU in Donor Health and Genomics |
| Organisation | NHS Blood and Transplant (NHSBT) |
| Department | National Blood Service |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge is a cross-disciplinary unit established to address major questions about the health of blood donors and produce evidence-based strategies to enhance donor safety and ensure sustainability of blood supply. We are the grant holders and managers of this unit. |
| Collaborator Contribution | The Unit is building and exploiting exceptionally large and detailed "living laboratories" of healthy participants who consent to frequent and active engagement in research studies (eg, recall-by-genotype, periodic re-attendance, wearing of devices, linkage with e-health records). For example, leveraging our strategic relationship with NHSBT, we have commenced linkage of >1M blood donors to e-health records. As a proof-of-concept study, we have already enrolled 50,000 donors into the INTERVAL Study in which we have commenced cohort-wide 15X whole genome sequencing, measured >5000 molecular phenotypes (eg, lipids, metabolites, proteins), conducted an advanced analysis of the cellular composition of the blood, employed accelerometry devices at scale and measured genome-wide genotypes. |
| Impact | The goals of this new Unit are to combine cutting-edge tools from genomics, biology and population health science to address key questions about the aetiology of important disorders (such as the health consequences of iron deficiency), to improve the safety and precision of blood donation, and to build and use major genomic resources that enable the study of important chronic diseases of wider relevance. This unit combined the disciplines of clinical studies, functional genetics, epidemiology and statistics/bioinformatics. |
| Start Year | 2015 |
| Description | NIHR BTRU in Donor Health and Genomics |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Human Complex Traits |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge is a cross-disciplinary unit established to address major questions about the health of blood donors and produce evidence-based strategies to enhance donor safety and ensure sustainability of blood supply. We are the grant holders and managers of this unit. |
| Collaborator Contribution | The Unit is building and exploiting exceptionally large and detailed "living laboratories" of healthy participants who consent to frequent and active engagement in research studies (eg, recall-by-genotype, periodic re-attendance, wearing of devices, linkage with e-health records). For example, leveraging our strategic relationship with NHSBT, we have commenced linkage of >1M blood donors to e-health records. As a proof-of-concept study, we have already enrolled 50,000 donors into the INTERVAL Study in which we have commenced cohort-wide 15X whole genome sequencing, measured >5000 molecular phenotypes (eg, lipids, metabolites, proteins), conducted an advanced analysis of the cellular composition of the blood, employed accelerometry devices at scale and measured genome-wide genotypes. |
| Impact | The goals of this new Unit are to combine cutting-edge tools from genomics, biology and population health science to address key questions about the aetiology of important disorders (such as the health consequences of iron deficiency), to improve the safety and precision of blood donation, and to build and use major genomic resources that enable the study of important chronic diseases of wider relevance. This unit combined the disciplines of clinical studies, functional genetics, epidemiology and statistics/bioinformatics. |
| Start Year | 2015 |
| Description | NIHR BTRU in Donor Health and Genomics |
| Organisation | University of Oxford |
| Department | Nuffield Division of Clinical Laboratory Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge is a cross-disciplinary unit established to address major questions about the health of blood donors and produce evidence-based strategies to enhance donor safety and ensure sustainability of blood supply. We are the grant holders and managers of this unit. |
| Collaborator Contribution | The Unit is building and exploiting exceptionally large and detailed "living laboratories" of healthy participants who consent to frequent and active engagement in research studies (eg, recall-by-genotype, periodic re-attendance, wearing of devices, linkage with e-health records). For example, leveraging our strategic relationship with NHSBT, we have commenced linkage of >1M blood donors to e-health records. As a proof-of-concept study, we have already enrolled 50,000 donors into the INTERVAL Study in which we have commenced cohort-wide 15X whole genome sequencing, measured >5000 molecular phenotypes (eg, lipids, metabolites, proteins), conducted an advanced analysis of the cellular composition of the blood, employed accelerometry devices at scale and measured genome-wide genotypes. |
| Impact | The goals of this new Unit are to combine cutting-edge tools from genomics, biology and population health science to address key questions about the aetiology of important disorders (such as the health consequences of iron deficiency), to improve the safety and precision of blood donation, and to build and use major genomic resources that enable the study of important chronic diseases of wider relevance. This unit combined the disciplines of clinical studies, functional genetics, epidemiology and statistics/bioinformatics. |
| Start Year | 2015 |
| Description | NMR Metabolomics |
| Organisation | Brainshake |
| Country | Finland |
| Sector | Private |
| PI Contribution | Provided samples from 50,000 participants in INTERVAL study. |
| Collaborator Contribution | Assays complete for all 50,000 samples, ~240 metabolites measured. |
| Impact | Publication manuscripts in preparation |
| Start Year | 2014 |
| Description | Novartis |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | 1) Characterization of associations of Lp(a)-related variants with Lp(a) concentration 2) Characterization of associations of Lp(a)-related variants with coronary heart disease (CHD) risk 3) Inclusion of additional results on some Lp(a)-related variants with CHD risk 4) Assessment of potential additivity of Lp(a) pathways and LDL-C pathways in CHD 5) "Phenome scanning" to explore broader phenotypic consequences of genetic Lp(a)-lowering |
| Collaborator Contribution | Financial support of £355,000 |
| Impact | Publication: 10.1001/jamacardio.2018.1470 Novartis Trial Board Presentation (Adam Butterworth) IGMM Seminar University of Edinburgh (Adam Butterworth) |
| Start Year | 2017 |
| Description | Proteomics - SomaLogic |
| Organisation | SomaLogic |
| Country | United States |
| Sector | Private |
| PI Contribution | We have provided 3500 samples from the INTERVAL study for analysis on SomaLogic's platform (approx. 1129 proteins measured). |
| Collaborator Contribution | Analysis of 3500 samples at a discounted price |
| Impact | Receiving data from platform; publication manuscripts in preparation |
| Start Year | 2015 |
| Description | Sanger Sequencing |
| Organisation | The Wellcome Trust Sanger Institute |
| Department | Human Genetics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of samples from INTERVAL Study and collaboration on analysis and publication manuscript preparation |
| Collaborator Contribution | Whole genome and whole exome sequencing of samples from the INTEVAL Study |
| Impact | Data received on ~4500 samples so far |
| Start Year | 2015 |
| Description | The Cambridge-Baker Systems Genomics Initiative |
| Organisation | Baker IDI Heart and Diabetes Institute |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Contributions include expertise and input from my research team to identify and explore the opportunities for joint research collaboration to 1) meet the next generation of challenges in cardiometabolic disease screening and prevent 2) identification and characterisation of drug targets through multi-omic analysis 3) development of transformational analytic methods that will drive the subsequent research epoch. My group will provide data analysis capacity and training resources to the Baker institute. Other contributions include: paying 50% of employment costs of Prof Inouye, 1 FTE Postdoc position, able to supervise PhD students;, $30,00pa travel support, accommodation and IT facilities for the CBSGI. This collaboration will be initially for five years and started June 2018. |
| Collaborator Contribution | The Baker Node will provide access to datasets, and other intellectual resources. Furthermore the Baker Node will provide 50% of the employment costs of Prof Inouye, 3 x 1FTE postdoc positions, travel support ($30,000 pa), accommodation and IT facilities for the CBSGI, access grant funding to expand capacity. |
| Impact | Publications: https://doi.org/10.1371/journal.pgen.1007607 https://doi.org/10.1016/j.jacc.2018.07.079 10.7554/eLife.35856 https://doi.org/10.1161/CIRCGEN.118.002234 https://doi.org/10.1093/nar/gky780 https://doi.org/10.1016/j.chom.2018.08.005 https://doi.org/10.1038/s41588-018-0117-9 Committees: Cambridge Baker Experimental Working Group Target validate of in silico discoveries University of Cambridge / Baker Institute Selection Committee: MRC PhD studentships in Data Science / Artificial Intelligence University of Cambridge Symposiums/seminars - Health Data Research UK: Cambridge, Polygenic risk scores and multiple -omics, Cambridge - Alfred Grand Rounds, Genomic risk and precision medicine: Or how I learned to stop worrying and love computational biology, Melbourne - Million Veterans Project Retreat, Integrative omics analysis, Downing College, Cambridge |
| Start Year | 2018 |
| Description | 16th Symposium on nutrition, lipids and atherosclerosis |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2009 |
| Description | 3rd International Symposium Integrated Biomarkers in Cardiovascular Diseases |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2008 |
| Description | A short talk on the genetics of heart disease and risk calculation both for environmental and genetic factors at the Cambridge Science Festival 2017. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | A short talk on the genetics of heart disease and risk calculation both for environmental and genetic factors at the Cambridge Science Festival 2017. Intended to disseminate research to the general public. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Alan Turing Institute presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Amgen Lipoprotein(A) Advisory Board |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Attendance in an advisory capacity at Amgen's Lipoprotein(a) advisory board meeting. Chance to provide insight and perspective to Industry on this topic. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Annual conference of the International Society for Clinical Biostatistics |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2009,2012,2013,2014 |
| Description | Article in NHSBT's The Donor Magazine (BTRU, INTERVAL, COMPARE) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Contributed an article to one of our partners - NHS Blood and Transplant's - magazines, which has significant reach across their donor groups and the research reported has impacted NHSBT strategy and processes. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.blood.co.uk/news-and-campaigns/the-donor-autumn-2018/new-haemoglobin-test/ |
| Description | Ask a Scientist (Amy Mason) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | A Skype call - 'Ask a Scientist' - with a group of 30 American school children, aged 9 years old (2018). Two Skype calls - 'Ask a Scientist' - with a group of primary school children (UK) and a group of American school children (2019). Brief, simple description of research work, and they could ask questions about what a statistician did. |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021 |
| URL | http://www.skypeascientist.com |
| Description | Astra Zeneca rountable discussion re CVD research |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation given at Roundtable Discussion focussed on Industry funded research programme ( One Brave Idea) to Industry colleagues. |
| Year(s) Of Engagement Activity | 2017 |
| Description | AstraZeneca Annual Genomics Partners Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Talk on ongoing recall-studies with volunteers from the Cambridge BioResource, delivered to stakeholders at AstraZeneca. |
| Year(s) Of Engagement Activity | 2006,2017 |
| Description | AstraZeneca Annual Genomics Partners Workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Keynote speech given at an Astra Zeneca partners Conference which sparked debate. |
| Year(s) Of Engagement Activity | 2017 |
| Description | AstraZeneca Centre for Genomics Research Annual Collaborators meeting (Professor John Danesh, Professor Emanuele Di Angelantonio, Dr Adam Butterworth) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation with title "using genomic and molecular information in the INTERVAL study to inform AZ therapeutic target prioritisation" at the AstraZeneca Centre for Genomics Research Annual Collaborators. Presenting the results of the collaboration with AstraZeneca and get their feedback, to inform future work. To obtain insight and input from i) leading external genomics experts and ii) cardiovascular and renal metabolism geneticists, on the techniques and strategies to identify novel genetic drivers of disease, as part of AstraZeneca's company-wide Genomics Initiative (2019). |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | BBC Radio Cambridgeshire interview |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Radio interview about a paper we had recently published in the European Heart Journal about obesity and physical fitness. |
| Year(s) Of Engagement Activity | 2017 |
| Description | BBC Radio Wales Interview (Clare Oliver-Williams) |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Discussed research project findings on BBC Radio Wales morning show. Increased awareness/knowledge of cardiovascular disease. |
| Year(s) Of Engagement Activity | 2018 |
| Description | BHF Cambridge CRE Annual research meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Annual British Heart Foundation Cambridge Centre visit - presentation overview of theme (Population Sciences) which sparked questions and discussion. |
| Year(s) Of Engagement Activity | 2017 |
| Description | BHF Cambridge Centre for Cardiovascular Research Excellence Annual Symposium |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Annual BHF Cambridge Centre for Cardiovascular Research Excellence Symposium. Session of population Chaired which sparked questions and debate. |
| Year(s) Of Engagement Activity | 2017,2018,2019,2020,2021 |
| Description | BTRU Advisory Committee Workshop (BTRU) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | An opportunity for members of the public serving on a formal committee to network with researchers and each other and to hear updates about research being conducted. Feedback from members of the public was very positive - they reported having a much better understanding about our research. We continue to hold workshops for our public volunteers in 2019. This year, we included trainee development by having our PhD students give presentations to the public and then discuss the clarity of written and verbal work meant for the public. |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| Description | BTRU Directors Meeting (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Third sector organisations |
| Results and Impact | Meeting between the leaders of the four Blood and Transplant Research Units with NIHR and NHSBT, in order to discuss research progress and strategy. |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| Description | BTRU Seminar Series (BTRU) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Speakers invited from around the world to talk about their research to academics, students, funding body representatives, charity representatives and members of the public. Numerous research collaborations have arisen from these talks, as well as increased awareness and confidence in members of the public, who have been given the opportunity to interact with world-class researchers. We continue to organise these seminars, which provide opportunities for our public volunteers to hear about related work being conducted around the world, as well as meet new scientists and interact with our scientists and students (2019). |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| URL | https://www.youtube.com/channel/UCeS9CPB2_QGcBsnORnNQyjQ |
| Description | BTRU and Study Management Committee meetings (BTRU, STRIDES) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | A formal meeting between researchers, funding body representatives, students and members of the public, in order to discuss the Unit's research or design studies. The meetings have enabled better collaboration and influenced study design, through public input. Our public volunteers continue to be active members of these committees (2019). |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| Description | Big Data Institute presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Presented research at the big data institute in Oxford, this lead to questions and collaborations on a new direction of research. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Briefing pharmaceutical companies |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research/funding |
| Year(s) Of Engagement Activity | 2010,2011,2012,2013,2014,2015,2016 |
| Description | British Heart Foundation, Health Informatics presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presented work on key findings on published papers Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2014 |
| Description | CAPABLE Bangladesh Launch |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Bangladesh launch of CAPABLE programme, talks given, press spoken to and site visited. Generated lots of debate and in country press articles. |
| Year(s) Of Engagement Activity | 2018 |
| Description | CAPABLE General Assembly (John Danesh) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Annual general assembly of CAPABLE programme, gathering of all collaborators, staff members, supporters, extended network, donors and other stakeholders. Talks, debates, working groups. This was a talk and discussion between Cambridge and Dhaka for a working collaboration to help improve the lives of the Bangladeshi people (2019). |
| Year(s) Of Engagement Activity | 2018,2019 |
| URL | http://www.capable-bangladesh.org/capable-in-popular-media/meeting-september-2018-uk/ |
| Description | CAPABLE workshop in Bangladesh (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Travel to Dhaka to plan implementation of CAPABLE study, with Scientific Planning Committee Meeting, site visits and meeting collaborators |
| Year(s) Of Engagement Activity | 2018 |
| Description | Cambridge BioResource Open Evening |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Study participants or study members |
| Results and Impact | Talk on the scientific background of the recall-studies, delivered to members of the volunteer panel of the Cambridge BioResource. The purpose was to introduce the research to the volunteers, answer questions, and invite them to participate in the studies. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.cambridgebioresource.group.cam.ac.uk/ |
| Description | Cambridge GCRF launch event |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Visit by politicians (Joe Johnson) and RCUK representatives to promote the GCRF projects funded at the University of Cambridge, including presentations to these stakeholders. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Cambridge Science Festival |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Helping out at the "Hands On" stall by the Division of Cardiovascular Medicine, giving a talk with 'Out-thinkers' and running a live action game event aimed at teaching 30 school children about the complexity of dealing with emerging epidemics. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.sciencefestival.cam.ac.uk/about/past-festivals/2018-festival |
| Description | Cambridge Science Festival (various) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | - Volunteered for a 'hands-on' stand at the festival, doing activities with children about the cardiovascular system.[Susan Burton, Clare Oliver-Williams, Amy Mason] - Gave a talk to the public (including Q&A) about relations between day-to-day cardiovascular functioning and thoughts, feelings, and behaviours. [Philippe Gilchrist] - Gave a talk to the public as part of Out Thinkers - just like white light is made by all the colour of the rainbow, so Science is made by the contributions of a cast of thousands. Meet some of these researchers in an informal setting and we hope to provide some laughs and a lot of science! Out Thinkers serves to showcase the talent of LGBT researchers, providing a platform where people can talk about their scientific work while truly being themselves.[Amy Mason] - Workshops for children using a game called Pathogen (live action game aims to give you an understanding of epidemics and the logistics of global disease prevention by putting you in the shoes of a global organisation responding to the outbreak of a new disease). [Amy Mason] - Gave a talk to the public (including Q&A) about what blood cells tell us about health and disease. [Emanuele Di Angelantonio, Will Astle, Lisa Schmunk] - Organised hands-on activities for children during the Biomedical Campus Hands-on Day (2019). - Gave a talk, including Q&A, "The role of genetics in cardiovascular health and disease" (2021). - Gave a talk, including Q&A, "Every drop counts: blood donors of the future" (2021). - Gave a talk, including Q&A, "Health Data Research and COVID-19" (2021). - Gave a talk, including Q&A, "Using health data to understand heart disease and COVID-19 risk" - Gave a talk, including Q&A, "Don't faint! The research protecting 100 blood donors every day" |
| Year(s) Of Engagement Activity | 2019,2021,2022 |
| URL | https://www.youtube.com/channel/UCeS9CPB2_QGcBsnORnNQyjQ |
| Description | Cambridge University-Baker Institute Partnership (Mike Inouye) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A new partnership with Cambridge University will significantly expand the capabilities of one of Australia's leading medical research institutes, Baker Heart and Diabetes Institute, to harness big data to target approaches in disease prediction and personalised medicine. Cambridge Baker Systems Genomics Initiative (CBSGI) Launch Event, to drive the development of next-generation analytics, uncover biological insights from multi-omic datasets and build clinically useful tools to predict and prevent disease (2019). |
| Year(s) Of Engagement Activity | 2018,2019 |
| URL | https://baker.edu.au/news/media-releases/cambridge-university-partnership |
| Description | Cambridge-Baker Experimental Working Group (Mike Inouye) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Working group to discuss research strategies. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Cambridge-Singapore Symposium (John Danesh) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Cambridge-Singapore Symposium in Addenbrookes with National University of Singapore covering various topics including cardiovascular disease aimed at clinical staff in the Hospital. |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | Cardiovascular Medicine Series, University of Oxford |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2011 |
| Description | Clinical Grand Rounds |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Presented work on key findings Raised awareness of topic and/or instigated discussion |
| Year(s) Of Engagement Activity | 2010,2011,2012 |
| Description | Cochrane Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presented work on key findings on published papers Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2014 |
| Description | Collaborative workshop MRC Biostatistics |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Collaborator meetings on Genetics projects |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2009,2010,2011,2012,2013,2014 |
| Description | EFRC Epidemiology/Statistics Working group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings on published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2008,2009,2010,2011,2012,2013,2014 |
| Description | EMBL and GRL Framework Partnership Agreement Renewal Event (John Danesh) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | EMBL and GRL Framework Partnership Agreement Renewal Event - Short talks regarding successful joint projects between EMBL-EBI and GRL. |
| Year(s) Of Engagement Activity | 2018 |
| Description | EuroPrevent |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2006,2008 |
| Description | European Researchers Night (Clare Oliver-Williams) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Engaging children's activities about being heart healthy. Increased awareness/knowledge of cardiovascular disease. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://ec.europa.eu/research/mariecurieactions/news/2018/european-researchers-night-2018-2019_en |
| Description | European Society of Cardiology Congress |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2011 |
| Description | European Society of Human Genetics (Barcelona) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | Oral presentation at the European Society of Human Genetics (Barcelona, 2016). |
| Year(s) Of Engagement Activity | 2016 |
| Description | First International Cohorts Summit (John Danesh) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | first forum for large-scale longitudinal cohorts worldwide to share best practices, discuss data sharing, explore standards, discuss common challenges, and explore the potential for a larger collaborative sequencing strategy. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Gave talk at Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Travelled to Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA and gave a talk on "Cardiovascular disease epidemiology in Cambridge: from aetiology to risk prediction" |
| Year(s) Of Engagement Activity | 2018 |
| Description | Genome Sequencing Project |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation given to an event with Astra Zeneca regarding potential collaboration involving strategic genome sequencing projects. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Genomics of Common Diseases conference (Baltimore) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Oral presentation at Genomics of Common Diseases conference (Baltimore) |
| Year(s) Of Engagement Activity | 2016 |
| Description | Giving seminar at Institute for Biomedicine EURAC, Bolzano, Italy (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Yearly travel to Institute for Biomedicine in Italy to give presentation to students and researchers on "Cardiovascular disease epidemiology in Cambridge: from aetiology to risk prediction". |
| Year(s) Of Engagement Activity | 2018,2019,2020 |
| Description | HDL Causality Genetics |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presented work on key findings on published papers Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2014 |
| Description | HDRUK Announcement as a chosen substantive site of HDRUK |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | National and local press release to publicise Cambridge being chosen as a substantive site of HDRUK. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Hands-on workshops for children (Pathogen) (Amy Mason) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Hands-on workshops for children, using the game Pathogen - a live action game which aims to give you an understanding of epidemics and the logistics of global disease prevention by putting you in the shoes of a global organisation responding to the outbreak of a new disease. The participants will be split up into small teams who will need to work together to keep this potentially dangerous disease under control. Each team will have its own activities to prioritise and complete, using a combination of statistics, medicine, biology and creative communication to save the world!" |
| Year(s) Of Engagement Activity | 2018 |
| Description | Harvard School of Public Medicine |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presented work on key findings on published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2011 |
| Description | Hills Road Sixth Form College - Big Biology Day (BTRU) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Information about our research and hands-on activities delivered for children considering their career options. Increased awareness of career opportunities in the sciences, beyond becoming an academic, and an opportunity to tell the public about our research. The Blood and Transplant Research Unit (BTRU) in Donor Health and Genomics participated in Big Biology Day again in 2019. |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | IGMM Seminar University of Edinburgh (Adam Butterworth) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr. Adam Butterworth gave the seminar "combining genomics and plasma proteomics to inform disease aetiology and therapeutic targets" as part of the IGMM Seminar Series. These weekly seminars attract distinguished scientists from around the world working in the fields of genetics, molecular medicine and cancer research, and whose research complements that being done at IGMM. Outcomes are improved awareness of research topics and findings, networking, making new linkages with other research. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Institute of Public Health Showcase |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2012,2014 |
| Description | Internal newsletters - Donor Population Health (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | An internal newsletter, shared with partnership colleagues (NHSBT), to share relevant information about research areas of interest. |
| Year(s) Of Engagement Activity | 2018 |
| Description | International Biometric Society |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | keynote/invited speaker |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2014 |
| Description | International Genetic Epidemiology Conference, Toronto |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Third sector organisations |
| Results and Impact | Presentation of research findings at the International Genetic Epidemiology Conference, Toronto. |
| Year(s) Of Engagement Activity | 2016 |
| Description | International symposium on large scale population-based biobank studies |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2011 |
| Description | Lipid and Atherosclerosis Society of Southern Africa |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2011 |
| Description | MRC PhD studentships in Data Science / Artificial Intelligence (Mike Inouye) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Selection committee for awarding PhD studentships in data science/artificial intelligence. |
| Year(s) Of Engagement Activity | 2018 |
| Description | MRC presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Media Interviews |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Presented work on key findings on published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2008,2009,2010,2011,2012,2013,2014,2015,2016 |
| Description | Mendelian Randomization Conference From Population Health to Pharmaceutical Developments |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A conference on aetiological epidemiology and causality in population health and clinical medicine |
| Year(s) Of Engagement Activity | 2015 |
| Description | Mendelian randomization symposium |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Society for Epidemiologic Research 45th Annual Meeting, 28-30th June 2012, Minneapolis, Minnesota, http://www.epiresearch.org/meeting/, "What Is an Odds Ratio and Why Does It Matter in Mendelian Randomization?", Stephen Burgess. Submission of a methodological paper based on ideas discussed |
| Year(s) Of Engagement Activity | 2012 |
| Description | NIHR BTRU & NHSBT PPIE Meetings (BTRU) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Third sector organisations |
| Results and Impact | An opportunity for patient and public involvement and engagement (PPIE) professionals to meet with funding body representatives and charity representatives, to collaborate and discuss best practice. We continue to be involved in these meetings, along with several of our public volunteers (2019). |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| Description | NIHR BTRU Training Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Poster presentation on research conducted in the BTRU in Donor Health and Genomics, delivered to members of the general public and other scientists. The purpose was to engage the public in the ongoing research. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.donorhealth-btru.nihr.ac.uk/ |
| Description | NIHR Blood and Transplant Research Unit Training Day (Emanuele Di Angelantonio, BTRU) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Workshop to allow clinicians, scientists, managers, directors, stakeholders and students to (1) explore how research activities support operational strategies for the Blood and Transplant Research Units, (2) update each other on research progress and (3) discuss collaborations. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Newsletter to update blood donor centre staff on study progress (BTRU) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Third sector organisations |
| Results and Impact | A newsletter to update Blood Donor Centre staff, who managed several of the Unit's studies, on research outcomes following the completion of the studies. Increased awareness about our research and enthusiasm to collaborate for future studies. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Newsletters to update study participants (BTRU, INTERVAL, COMPARE) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Periodic newsletters sent to study participants, in order to update them on research projects made possible by their participation. Newsletters have revitalised discussion about studies (some of which have finished but the data can be used in myriad way) and ideas for representing the research on the study websites. We continue to send newsletters to study participants for our closed and live studies. |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| URL | http://www.donorhealth-btru.nihr.ac.uk |
| Description | Novartis Trial Board Presentation (Adam Butterworth) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | A presentation to enlighten about research activities, network and build collaborations. |
| Year(s) Of Engagement Activity | 2018 |
| Description | PROCARDIS Lp(a) Workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2011 |
| Description | Poster discussion at the ESC Conference (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Led discussion at the ESC Barcelona Conference (2017) during poster presentation to encourage questions and consideration of topic. Participated in Congress in 2020. The ESC is a world leader in the discovery and dissemination of best practices in cardiovascular medicine. It is a volunteer-led, not-for-profit medical society. Members and decision-makers are scientists, clinicians, nurses and allied professionals working in all fields of cardiology. |
| Year(s) Of Engagement Activity | 2017,2020 |
| Description | Present at the donor session at the annual BBTS conference, Glasgow |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The audience in the donor session will comprise of medical and nursing professionals involved in blood donation. It is an educational programme to promote understanding and discussion in this topic. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentation at AHA Scientific Sessions in Chicago (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster Presentation: Cardiovascular Disease Risk Prediction Using Machine Learning: A Prospective Cohort Study of 423,604 Participants |
| Year(s) Of Engagement Activity | 2018 |
| Description | Presentation at BHF Centre of Excellence meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Presentation at BRC Scientific Advisory Board |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Presentation at Peking University Health Science Center, China |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Discussion on NSFC funded project of "Cardiovascular risk prediction for the Chinese population using big data: from discovery to application" for education and enagement. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentation at Wellcome Trust Target Validation Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Presentation at pre-meet on TRANSPOSE project at Sanquin, Amsterdam (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Meeting with international collaborators to update and discuss WP4 section of TRANSPOSE study |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | Presentation at the Australian Red Cross Blood Service |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Presentation to audience of blood service staff who work in predominantly donor collection, recruitment and the communication and marketing team, the researchers working within the blood service, related university partners and representatives from government agencies. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentation at the European Bioinformatics Institute |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Presentation for Sysmex Japan visit (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Opportunity for Cambridge to further strengthen its leading role on blood cell genomics and to bring tangible improvements to the diagnostic value of the Full Blood count analysis. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Presentation to CTSU in Oxford |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | Presented research at the CTSU in Oxford, this lead to many questions and post-presentation discussions and suggested new areas of research for some in the audience. Also lead to additional follow up from individuals in the following months showing interest in my area of research. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentation to Takeda |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Presenting at BEST Collaborative meeting in Florence (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Meeting of practitioners to discuss Biomedical Excellence for Safer Transfusion and present new research and up to date techniques |
| Year(s) Of Engagement Activity | 2018 |
| Description | Presenting at EUROPEAN CONFERENCE ON DONOR HEALTH & MANAGEMENT 2018 in Copenhagen (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chairing a session on Donor Health Studies and participating in a debate on IRON AND DONOR HEALTH - DIFFERENT APPROACHES TO MEASURING HB IN BLOOD DONORS INTERNATIONALLY with an update on the COMPARE study |
| Year(s) Of Engagement Activity | 2018 |
| Description | Presenting at IBST Conference, Toronto (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presenting in the Donors & Donation - Donor Safety Session to practitioners on new research and up to date techniques in this field. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Presenting poster session at Cambridge-Harvard Cardiorespiratory Research Meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | The purpose of the meeting was to showcase the high quality research in Cambridge that might foster future collaborations between the two universities. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Press release and media enquiries (Clare Oliver-Williams) |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Press release about research presented at a conference, leading to media enquiries. It was covered in national papers (e.g. the independent) as well as international press (e.g. Newsweek). Increased awareness/knowledge of cardiovascular disease. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.newsweek.com/kids-linked-heart-disease-risk-mothers-according-new-study-956066 |
| Description | Public involvement - requesting comments for study documentation (BTRU) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Numerous opportunities for members of our formal working groups to provide comment on our study documents and research. Comments were fed back to researchers and incorporated. As above, we continue to request feedback from our public volunteers on documentation for our live studies. |
| Year(s) Of Engagement Activity | 2018,2019,2020 |
| Description | Renewal of MRC/BHF Programme Grant |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Visit by Professor Chris Whitty, presentation given on BRC population health |
| Year(s) Of Engagement Activity | 2017 |
| Description | Research article for the Conversation (Clare Oliver-Williams) |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Wrote an article for the Conversation about research, which was re-published in the Sun, blogs and translated into French. Increased awareness/knowledge of cardiovascular disease. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://theconversation.com/avoir-des-enfants-augmenterait-le-risque-de-maladies-cardio-vasculaires-... |
| Description | Research meetings with BTRU Advisory Committee members (BTRU) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | Meetings between research leads and members of the public serving on an Advisory Committee, a formal group to ensure public involvement in our research activities. Members of the public have made significant contributions to the design of our studies and impacted the way that staff and students interact with public involvement and engagement activities. |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| URL | http://www.donorhealth-btru.nihr.ac.uk/involved/ |
| Description | Royal Statistical Society meeting on multivariate meta-analysis |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2009,2010 |
| Description | Speaker at workshop at Beijing Institute of Heart Lung and Blood Vessel Diseases, China |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Invited speaker for the workshop of "diagnosis and prognosis of survival for aortic dissection" with a view to discussion on potential collaboration |
| Year(s) Of Engagement Activity | 2017 |
| Description | Speaking at 1st International Symposium of Translation Medicine Luhe hospital in Beijing (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Traveled to Luhe hospital in Beijing to deliver up-to-date knowledge, technology and research findings to the medical field |
| Year(s) Of Engagement Activity | 2018 |
| Description | Speaking at BEST (Biomedical Excellence for Safer Transfusion) Collaborative meetings (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Meeting of practitioners to discuss Biomedical Excellence for Safer Transfusion and present new research and up to date techniques. Presentations given in Ireland and San Antonio (Texas) in 2019. Presentations given virtually in 2020. |
| Year(s) Of Engagement Activity | 2018,2019,2020 |
| URL | http://www.bestcollaborative.org |
| Description | Talk - Alfred Grand Rounds, Genomic risk and precision medicine (Mike Inouye) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk to researchers about the challenges of working in computational biology. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Talk at AstraZeneca |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presentation of findings from scientific research |
| Year(s) Of Engagement Activity | 2015 |
| Description | Talk at AstraZeneca Genomic Partners Workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Talk about my scientific research at a meeting of industry and academia |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk at British Atherosclerosis Society Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Talk about my scientific research |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk at Genomics of Common Diseases conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Talk about my scientific research at a conference |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk at NHSBT blood donor studies conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk about my scientific research |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk at NIHR Stroke Research Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Talk about my scientific research at a conference |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk at Therapeutic Target Validation conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Talk about my scientific research at a conference |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk at cardiovascular seminar series, Addenbrookes hospital, Cambridge |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | The audience were scientists, clinical fellows and students in cardiovascular research. The purpose was to educate and discuss current research. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Teaching at Short Course in Dhaka, Bangladesh (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Teaching on Short Course in Dhaka, Bangladesh organised by UK Universities to extend knowledge and educate as part of CAPABLE study |
| Year(s) Of Engagement Activity | 2018,2019,2020 |
| Description | Tiered Consent Workshops (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | As part of a research project on developing a tiered consent process for blood donors, members of the public were invited to participate in generating ideas, giving opinions and enriching discussions with stakeholders and researchers. Feedback from the researchers - about how public feedback had changed the project - was sent to the public volunteers who had attended the workshops (2019). |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | Twitter accounts for the Cardiovascular Epidemiology Unit, Blood and Transplant Research Unit and individual researchers |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Increased activity of all Twitter accounts, with the aim of engaging more members of the public and informing about our research outcomes. Increase in followers and awareness/knowledge about our research and opportunities in which to get involved (studentships, public involvement/engagement, etc).@DonorHealthBTRU @CAMBRIDGE_CEU |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| URL | https://twitter.com/cambridge_ceu?lang=en |
| Description | Update at TRANSPOSE Meeting at Finnish Red Cross Blood Service in Helsinki (Emanuele Di Angelantonio) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Meeting with international collaborators to update and discuss TRANSPOSE study |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | Website for Cardiovascular Epidemiology Unit, Blood and Transplant Research Unit, various studies and research partnerships |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Research activities written for the public (removing acronyms, short-hand, etc) and addition of Patient and Public Involvement and Engagement pages (see URL below). Other websites disseminate information about who we are and what w do, how to get involved (studentships, public involvement/engagement), partnerships and publications (as a means of sharing outcomes from our research activities). In 2019, new pages were added to the BTRU website about the new STRIDES study, the BioResource and lay summaries about some of our research into blood donor health. |
| Year(s) Of Engagement Activity | 2018,2019,2020,2021,2022 |
| URL | http://www.donorhealth-btru.nihr.ac.uk |
| Description | Wellcome Trust Sanger Institute |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented work on key findings. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2011,2012,2013 |
| Description | Workshop on genetic studies in the Bangladeshi population |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presented work on key findings on published papers Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2014 |
| Description | Workshop on genetic studies in the Pakistani population |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presented work on key findings and published papers. Raised awareness of topic and/or instigated discussion/further research |
| Year(s) Of Engagement Activity | 2010 |
| Description | presentation to stroke research audience |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | Presented research to a stroke research audience and had many questions a lot of enthusiasm for the work and new collaborations. |
| Year(s) Of Engagement Activity | 2017 |